The studies that provided the data for this review are all published and are specified in the references of this paper. All relevant data that were extracted from the eligible publications are within the paper and its Supporting Information files.

Introduction {#sec008}
============

Globally, stroke is the second most frequent cause of death.\[[@pone.0206163.ref001]\] There is a growing literature indicating that infections, particularly acute respiratory and urinary infections, may play a role in triggering vascular events.\[[@pone.0206163.ref002]\] Herpesviruses are a family of common viruses persisting latently after primary infection and reactivating periodically. The viruses induce a range of inflammatory effects,\[[@pone.0206163.ref002]\] potentially contributing to thrombogenesis, atherosclerosis, vasculopathy and platelet activation and thus an increased risk of stroke.

Six previous reviews support an association between herpes zoster (caused by the reactivation of varicella zoster virus (VZV)) and stroke.\[[@pone.0206163.ref003]--[@pone.0206163.ref008]\] One reported a risk ratio of 1.36 (95%CI 1.10--1.67) for the association between zoster and stroke pooled across six cohort studies,\[[@pone.0206163.ref004]\] whilst the other reviews found around 2-fold increased risk shortly after zoster, which decreased over the following year.\[[@pone.0206163.ref003], [@pone.0206163.ref005]--[@pone.0206163.ref007]\] Cytomegalovirus (CMV) is also hypothesised to modulate stroke risk, especially among immunocompromised populations\[[@pone.0206163.ref009]\] and a recent systematic review concluded that cytomegalovirus infection is associated with an increased risk of cardiovascular disease.\[[@pone.0206163.ref010]\]

Although these reviews have made a significant contribution, there are certain limitations, such as; exclusion of self-controlled case series (SCCS),\[[@pone.0206163.ref004]\] exclusion of studies among children,\[[@pone.0206163.ref003]--[@pone.0206163.ref008]\] limited subgroup analyses (only one study assessed whether antiviral therapy modified stroke risk)\[[@pone.0206163.ref007]\] and restricted scope by looking exclusively at clinically apparent zoster and stroke risk. Studies assessing any of the eight herpesviruses known to infect humans and utilising laboratory tests and serological analysis, as well as clinical diagnoses, could also help elucidate the role of latent, sub-clinical or clinical infection and stroke risk.

The primary objective of the systematic review was therefore to investigate whether patients with infection, or reactivation of, human herpesviruses are at increased risk of stroke,

Methods {#sec009}
=======

The protocol was published\[[@pone.0206163.ref011]\] according to the Preferred Reporting Items for Systematic Reviews and Meta Analyses Protocols guidelines (PROSPERO registration number:CRD42017054502).

Study designs and characteristics {#sec010}
---------------------------------

Eligible study designs included cohort, case-control, case-cohort, case-crossover and SCCS designs. Randomised controlled trials investigating prevention or treatment of herpesvirus infection or reactivation (using vaccines or antiviral agents) were also eligible. We excluded cross-sectional studies, ecological studies, case-series, case-reports and reviews. Studies were required to report an effect estimate or the data that allow its calculation. We placed no restrictions on time period, publication status, language, geographical setting or healthcare setting.

Participants {#sec011}
------------

Eligible studies included human participants. No restrictions were placed participants' on age or immunosuppression status.

Exposure {#sec012}
--------

The exposures of interest were infection with, or reactivation of, the eight human herpesviruses: specifically, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), VZV, Epstein-Barr virus (EBV), CMV, herpesvirus 6, 7, and 8. The exposure definition could be self-reported or a confirmed diagnosis, either through clinical or laboratory criteria. Vaccination against herpesviruses (e.g. Zostavax vaccine) and treatment for herpesviruses (e.g. antivirals) were also considered as effect modifiers, to investigate whether preventing or treating human herpesviruses attenuated stroke risk.

Comparators {#sec013}
-----------

Eligible studies were required to include a comparison group of people (or person time for SCCSs or case-crossover) without the herpesvirus exposure of interest.

Outcomes {#sec014}
--------

Studies were included if stroke (first ever or subsequent) was an outcome, clinically diagnosed or self-reported. Those studies meeting the inclusion criteria were additionally assessed for secondary outcomes: TIA\[[@pone.0206163.ref012]\] and subtypes of stroke (ischaemic versus haemorrhagic).

Information sources {#sec015}
-------------------

We searched for eligible articles in six databases, originally from dates of inception to January 2017, and then again in July 2018 limited to the years 2017 and 2018. The databases included Cochrane Central Register of Controlled Trials, Embase, Global Health, Medline, Scopus and Web of Science. We additionally searched the clinical trials registers (ClinicalTrials.gov) and grey literature sources, including the New York Academy of Medicine Grey Literature Report ([www.greylit.org](http://www.greylit.org/)) and the Electronic Theses Online Service through the British Library ([http://ethos.bl.uk](http://ethos.bl.uk/)).

Search strategy {#sec016}
---------------

We searched medical subject heading terms and free text (in the title and abstract) for the concepts 'human herpesviruses' and 'stroke' (combined with the Boolean logic operator AND). Search terms were developed for the database Medline, reviewed by all collaborators and subsequently transcribed into search terms for the remaining databases (supplementary information [S1 Appendix](#pone.0206163.s001){ref-type="supplementary-material"} for search terms). Reference lists of eligible articles and relevant reviews were scanned for additional papers.

Study selection {#sec017}
---------------

Eligibility assessment was performed independently in a blinded standardized manner by two reviewers (CWG and HF); all retrieved titles and abstracts were screened.

Data collection process {#sec018}
-----------------------

Data were extracted using a pre-defined standardised template. Extraction criteria were based on the PICOS\[[@pone.0206163.ref013]\] (Population, Intervention, Comparator, Outcomes and Study design) framework. As this is an aetiological study, "exposure" replaced "intervention" and "study characteristics" broadened to "study design" ([S3 Appendix](#pone.0206163.s003){ref-type="supplementary-material"} for all items extracted). We also recorded: the most fully adjusted effect estimates (odds ratios, hazard ratios, incidence rate ratios, risk ratios) for the association between the exposure and stroke; confounders adjusted for; and results of additional analyses relevant to our non-primary objectives. If there were no events in one arm of the study, a continuity correction was applied (adding 0.5 to each cell\[[@pone.0206163.ref013]\]).

Risk of bias in individual studies {#sec019}
----------------------------------

Two authors independently assessed risk of bias in three studies and HF completed the remaining studies. In keeping with the Cochrane Collaborations approach,\[[@pone.0206163.ref014]--[@pone.0206163.ref016]\] a pre-specified set of domains were considered, including bias due to: 1) confounding; 2) selection of participants; 3) differential and non-differential misclassification of exposure and outcome; 4) missing data; and 5) reverse causation. For each domain, *a-priori* criteria were set-out to assign 'high', 'low', 'moderate', or 'unclear' risk. A summary risk of bias table was produced; when a domain had more than one item the highest risk of bias judgment was used (unless the only item at high-risk was non-differential misclassification, which would bias results toward the null).

Synthesis of results {#sec020}
--------------------

We synthesised the results into a narrative, grouping studies by herpesvirus exposure and study design; subgroup analyses were also described. We classified exposures as past infection or recent infection/reactivation. IgM and IgA antibodies, and DNA, are present in the blood for a limited period following herpesviruses exposure, therefore their presence suggests recent infection or reactivation (though IgM has poor sensitivity for detecting acute infections and poor specificity in immunosuppressed).\[[@pone.0206163.ref017]\] Conversely, IgG antibodies, although also raised during an acute infection or reactivation, remain during latent infection, therefore were classified as a past infection.\[[@pone.0206163.ref017]\] We also presented results from studies of high versus low IgG titre, as high IgG titre may reflect recent reactivation.

When at least two studies assessed the same herpesvirus as a stroke risk factor, meta-analysis was considered. For pooling, we required studies to have identical study designs, the same measurement for the herpesvirus (e.g. IgG seropositivity) and identify the outcome within a similar time-frame. We pooled effect sizes (referred to as "summary estimates") irrespective of the type of effect estimate, due to stroke being rare. Random effects meta-analysis was used throughout, to ensure a consistent approach to all analyses was employed; the I^2^ statistic indicated moderate heterogeneity (I^2^\>25%) for many subgroups. We investigated sources of heterogeneity (where there were at least three studies in the meta-analysis) by removing studies at high-risk of bias.

Quality of the evidence {#sec021}
-----------------------

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE)\[[@pone.0206163.ref018]\] approach was used to summarise the quality of cumulative evidence for each herpesvirus on stroke. Evidence was categorised as 'high', 'moderate', 'low' or 'very low' quality, with observational studies starting as 'low'; five reasons to rate down and three reasons to rate up the quality of evidence, were then considered.\[[@pone.0206163.ref019]\] Full criteria for grading is in [S4 Appendix](#pone.0206163.s004){ref-type="supplementary-material"}. We assessed publication bias when there were at least 10 studies by creating a funnel plot: effect estimates for the exposure on stroke risk were plotted against standard errors of the log odds, and symmetry was assessed visually and using Begg's test for small-study effects.\[[@pone.0206163.ref020]\]

Ethics {#sec022}
------

As this is a systematic review, ethical approval is not required.

Results {#sec023}
=======

In our initial search 5012 titles and abstracts were screened and 41 observational studies were selected for review ([Fig 1](#pone.0206163.g001){ref-type="fig"}). Our updated search retrieved 607 studies, of which seven were selected for review, making a total of 48 studies for the final review.

![Flow diagram of study selection.](pone.0206163.g001){#pone.0206163.g001}

Study methods and results are summarised in Tables [1](#pone.0206163.t001){ref-type="table"} and [2](#pone.0206163.t002){ref-type="table"} respectively, risk of bias for individual studies in [Table 3](#pone.0206163.t003){ref-type="table"} ([S5 Appendix](#pone.0206163.s005){ref-type="supplementary-material"} for detailed justification) and GRADE assessment in [Table 4](#pone.0206163.t004){ref-type="table"}. Results and meta-analyses are displayed in Figs [2](#pone.0206163.g002){ref-type="fig"}--[4](#pone.0206163.g004){ref-type="fig"}.

![Effect of clinically diagnosed herpes zoster on stroke risk by study design and length of follow-up.\
†Outcome was ischaemic stroke ‡Outcome was stroke/TIA μ: among patients 50--60 years of age. •Study population was immunosuppressed \*Comparator group was person time 366-730days after HZ.](pone.0206163.g002){#pone.0206163.g002}

![Effect of CMV (serological evidence of infection or clinical reactivation) on stroke risk.\
†Outcome was ischaemic stroke ‡Outcome was stroke/TIA •Study population was immunosuppressed. ‼No age adjustment/matching for age.](pone.0206163.g003){#pone.0206163.g003}

![Effect of EBV, HSV, VZV infection, clinically diagnosed varicella and VZV vaccination on stroke risk.\
†Outcome was ischaemic stroke ‡Outcome was stroke/TIA ‼No age adjustment/matching for age.](pone.0206163.g004){#pone.0206163.g004}

10.1371/journal.pone.0206163.t001

###### Study characteristics.

![](pone.0206163.t001){#pone.0206163.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, yr                                          Design          Study period               Setting                                                                                              Study population at recruitment                                                                                                                                                                                                                                             Exposure definition and ascertainment                                                                                                                            Comparator definition and ascertainment                                                                                   Outcome type                                                         Outcome definition and ascertainment
  --------------------------------------------------- --------------- -------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **VZV reactivation---Herpes zoster**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Breuer, 2014\[[@pone.0206163.ref022]\]              Cohort          2002--2010                 UK, primary care records from THIN                                                                   Adults (≥18 yr) with HZ and age (± 2 yr), sex and GP practice matched (2:1) patients with no HZ.                                                                                                                                                                            Non-recurrent HZ: Read codes                                                                                                                                     Patients without an HZ Read code                                                                                          Primary: stroke or TIA\                                              First ever incident stroke or TIA: Read codes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic, haemorrhagic or unspecified stroke             

  Calabrese, 2017\[[@pone.0206163.ref023]\]           Cohort          2006--2013                 United States, Medicare claims data                                                                  Adults ≥65 yr with HZ, ≥12mo follow-up at entry, inflammatory disease (ankylosing spondylitis/ IBD/ psoriasis/ psoriatic arthritis/RA), no prior stroke or antiviral therapy                                                                                                Inpatient/outpatient HZ: ICD-9 diagnosis code AND no same day code for zoster vaccine                                                                            Time after HZ divided into 3 periods: 0--90 days; 91--365 days; 366--730 days (reference group).                          Primary: Any stroke\                                                 Hospitalised stroke: ICD-9 diagnosis code in any position on hospital claim.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic stroke                                          

  Hosamirudsari, 2018 \[[@pone.0206163.ref021]\]      Case-control    2015--2017                 Iran, individuals attending a single hospital                                                        Adults (aged 30--90 years) admitted for stroke, and controls were stroke-free individuals                                                                                                                                                                                   Self-reported HZ infection in the last 6 months, collected by a team of healthcare specialists.                                                                  No self-report of HZ infection                                                                                            Stroke                                                               Stroke diagnosed by neurologist and confirmed by brain imaging

  Kang, 2009\[[@pone.0206163.ref024]\]                Cohort          1997--2001                 Taiwan, National Health Research Institute claims database                                           Patients (≥18 yr) with HZ and no history of stroke, matched to 3 patients (age, sex) with no history of HZ or stroke before 2001.                                                                                                                                           Treatment for HZ in ambulatory care: ICD-9 codes.                                                                                                                Patients without a history of HZ                                                                                          Primary: stroke (any)\                                               ICD-9 codes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic, haemorrhagic                                   

  Kim, 2017\[[@pone.0206163.ref032]\]                 Cohort          2002--2013                 Korea, sample of national health insurance database                                                  Patients (age unknown) with HZ propensity score matched to those without HZ.                                                                                                                                                                                                HZ diagnosis: ICD-10 codes                                                                                                                                       Patients without HZ                                                                                                       Stroke                                                               Newly diagnosed stroke: ICD-10 codes

  Kwon, 2016\[[@pone.0206163.ref025]\]                Cohort          2003--2013                 Korea, 1 million sample of national health insurance database                                        All patients (\>18 yr) in database: those with HZ or stroke during 1st yr of observation period excluded.                                                                                                                                                                   First HZ in the observation period: ascertained from ICD-10 codes.                                                                                               Patients without a history of HZ.                                                                                         Stroke/TIA                                                           First ever stroke or TIA: ICD-10 codes

  Langan, 2014\[[@pone.0206163.ref037]\]              SCCS            1987--\                    UK, CPRD; routinely collected database of primary and secondary care records.                        Adults (≥18 yr) with 1st ever HZ and stroke. Exclusions: incident TIA, subarachnoid haemorrhage, encephalitis in 12 mo after stroke.                                                                                                                                        1st ever HZ: Read and ICD-10 codes. Exposed period: day after HZ to 12 mo (wk 1--4, 5--12, 13--26, and 27--52).                                                  All observation time around exposed period, with the exception of the day of HZ and 4-wk pre-HZ                           Primary: Arterial stroke\                                            First ever stroke: Read codes in CPRD and ICD-10 codes in linked hospital data.
                                                                      2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Secondary: cerebral infarction, haemorrhagic or unspecified stroke   

  Liao, 2017\[[@pone.0206163.ref033]\]                Cohort          2000--2011                 Taiwan, National Health Research Institute claims database                                           Adults (≥18 yr) with rheumatoid arthritis. Those with HZ matched (on age, sex, disease duration) to those without HZ. Excluded those with HZ or stroke prior to entry                                                                                                       HZ diagnosis after study entry: ICD-9 codes.                                                                                                                     Patients without HZ                                                                                                       Stroke                                                               ICD-9 codes

  Lin, 2010\[[@pone.0206163.ref026]\]                 Cohort          2003--2005                 Taiwan, National Health Research Institute claims database                                           Immunocompetent adults (≥ 18 yr) with HZO, matched (age, gender) to 3 without HZO. Excluded those with stroke prior to entry.                                                                                                                                               Patients seeking ambulatory care for HZO (patients with HZO in the previous yr excluded: ICD-9 code (053.2)                                                      Patients without HZ. First ambulatory care visit in 2004 was assigned their index date.                                   Stroke                                                               Not specified: most likely from ICD-9 codes

  Minassian, 2015\[[@pone.0206163.ref035]\]           SCCS            2006--2011                 United States, Medicare claims data                                                                  Patients (≥65 yr) with HZ and stroke / TIA. Excluded if had HZ or vascular events pre-entry or subarachnoid haemorrhage ever or encephalitis in 12 mo post-stroke                                                                                                           HZ episode; ICD-9 code with antiviral 7 days before or after HZ. Exposed period: 12-mo after HZ (wk 1, wk 2--4, 5--12, 13--26, and 27--52).                      All other observation time made up the baseline (unexposed) period, except the day of and the 4 wk before HZ diagnosis.   Primary: ischaemic stroke\                                           Stroke: ICD-9 codes in outpatient and inpatient (primary diagnostic field) records
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary:\                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             haemorrhagic stroke                                                  

  Patterson, 2018\[[@pone.0206163.ref034]\]           Cohort          2007--2014                 United States, Medicare and MarketScan data                                                          Adults (\> = 18) at HZ diagnosis, propensity matched to HZ-free controls.                                                                                                                                                                                                   HZ diagnosis                                                                                                                                                     Patients without HZ                                                                                                       Stroke and TIA                                                       Not specified: most likely from ICD-9 codes

  Schink, 2016\[[@pone.0206163.ref036]\]              SCCS            2004--2011                 Germany,health claims data from 4 insurance providers, hospitalisations and outpatients data         Patients (any age) with HZ and stroke, ≥12 mo follow-up, no history of stroke or HZ in 12 mo pre-cohort entry.                                                                                                                                                              1st or recurrent HZ: ICD-10 code or antiviral with HZ outpatient-diagnosis. Exposed period: up to 12 mo from HZ (0--2 wk, 3--4 wk, 2--3 mo, 4--6 mo, 7--12 mo)   All follow-up time outside exposed period.                                                                                Primary: First stroke\                                               Hospitalised stroke: ICD-10 codes for main discharge diagnosis in hospitalisation data. Admission date taken as onset date
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic, haemorrhagic, stroke unspecified or TIA.       

  Sreenivasan, 2013\[[@pone.0206163.ref027]\]         Cohort          1995--2008                 Denmark, routinely collected civil registration data and health registers.                           All Danish adults (≥18 yr) alive during study period. Persons with outcome before start of follow-up were excluded.                                                                                                                                                         HZ treated with antivirals;\                                                                                                                                     Cohort members with no prior history of acyclovir, valacyclovir or famciclovir prescriptions.                             Stroke and TIA (as a composite outcome)                              ICD 8 and 10 codes, from National Patient Registry; a database of all hospitalisations, outpatient visits and emergency department visits.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  acyclovir prescription (800 mg in packages of 35\                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  tablets)                                                                                                                                                                                                                                                                                                                                                        

  Sundström, 2015\[[@pone.0206163.ref028]\]           Cohort          2008--2010                 Sweden, routinely collected healthcare data from one county.                                         All incident cases of HZ occurring during the study period and the general population in the country. No age restrictions.                                                                                                                                                  HZ from ICD-10 codes, with no diagnosis of HZ in the previous yr.                                                                                                General population in the country (no further information given).                                                         Stroke                                                               ICD-10 diagnosis within 1 yr of HZ diagnosis.

  Tseng, 2011\[[@pone.0206163.ref065]\]               Cohort          2007--2010                 United States, Kaiser Permanente Southern California health care                                     HZ cases (≥50 yr) without history of stroke 1 yr pre-HZ, matched (age, date of HZ, setting of medical care) to patients without HZ                                                                                                                                          HZ cases who had received treatment for HZ during the study period                                                                                               Patients without HZ                                                                                                       Stroke                                                               Incident stroke, identified from hospitalisation records with a primary diagnosis as stroke.

  Yawn, 2016\[[@pone.0206163.ref031]\]                Cohort          1986--2011                 United States, medical records from Olmsted County.                                                  All adults (≥50 yr) with HZ, matched (sex, age (+/- 1 yr)) to patients without HZ. Patients with history of stroke excluded.                                                                                                                                                1st/recurrent HZ; ICD-9 code and HZ clinical symptoms in medical records                                                                                         Patients with no HZ diagnoses in five yr prior to cohort entry.                                                           Stroke                                                               Diagnostic codes from hospital admissions or death records, \<30 days before cohort entry, or until cohort exit.

  **CMV infection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Coles, 2003\[[@pone.0206163.ref038]\]               Case-cohort     1995--1998                 Australia, Busselton Health Survey, and linked hospital and death data                               Adults (40--89 yr) developing stroke and random sample of non-stroke adults, without CVD at baseline, with serum samples from 1981.                                                                                                                                         IgG antibodies: avidity assay (AxSym)\                                                                                                                           Participants without IgG antibodies to CMV                                                                                Stroke                                                               First stroke; from ICD-10 codes and defined as either admission to hospital with any diagnosis of stroke or death from stroke.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  High level sample = ≥250.                                                                                                                                                                                                                                                                                                                                       

  Fagerberg, 1999\[[@pone.0206163.ref039]\]           Cohort          1987--1995                 Sweden, men from intervention study with hypertension and ≥1 other CVD risk factor.                  Men (50 to 72 yr). Of 508 recruited into intervention study, 164 (32%) randomly selected to participate in sub-studies.                                                                                                                                                     High IgG antibodies: MEIA on serological samples taken at entry and/or 3.5 yr later. High titre undefined                                                        Participants with low titres against CMV.                                                                                 Non-fatal stroke                                                     Independently coded by 2 physicians using hospital records, autopsy records, and death certificates.

  González-Quijada, 2015\[[@pone.0206163.ref040]\]    Case-control    2011--2013                 Spain, random sample of elderly patients from a single hospital                                      Cases (stroke patients) and controls (non-stroke patients) aged ≥65 yr (unmatched).                                                                                                                                                                                         High IgG antibodies: ELISA. Defined as top quartile of serological values. Date samples taken unknown.                                                           CMV seropositive participants without high-titre IgG antibodies.                                                          Ischaemic stroke or TIA                                              Prevalent or incident ischaemic stroke and/or TIA: determined by imaging data or neurology / internal medicine specialists.

  Huang, 2012\[[@pone.0206163.ref041]\]               Case-control    1997--2000                 China, Stroke Hypertension Investigation in Genetics case-control study                              Stroke patients matched to controls without stroke (sex, age ±3 yr, geographic location, blood pressure category. Age unknown.                                                                                                                                              IgG, IgM antibodies: ELISA\                                                                                                                                      Participants without any CMV infection                                                                                    Primary: Any stroke\                                                 Stroke patients discharged from hospital with stroke in past 5 yr. Diagnosed by computer tomography or magnetic resonance imaging
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  DNA: PCR on plasma samples taken after stroke diagnosis (date unknown).                                                                                                                                                                                                                    Secondary: ischaemic and haemorrhagic.                               

  Kenina, 2010\[[@pone.0206163.ref042]\]              Case-control    Unclear                    Latvia, single hospital. Data collected through clinical evaluation and questionnaires.              Stroke patients and controls aged ≥42 yr.                                                                                                                                                                                                                                   IgG antibodies:plasma and sera using ELISA                                                                                                                       Participants without any CMV infection                                                                                    Primary: ischaemic\                                                  Stroke patients hospitalised in the Clinic of Neurology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: Atherotrombotic, Cardioembolic or Undetermined            

  Oliveras, 2003\[[@pone.0206163.ref043]\]            Cohort          1979--2000                 Spain, single hospital. Data collected retrospectively.                                              Patients who received renal transplants between 1979--2000.                                                                                                                                                                                                                 CMV infection from medical records: no further information provided                                                                                              Participants without any CMV infection                                                                                    Primary: Any stroke\                                                 Diagnosis based on clinical symptoms and brain CT scan or MRI.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic and haemorrhagic.                               

  Shen, 2011\[[@pone.0206163.ref044]\]                Case-control    2009                       China, inpatients and outpatients from neurology department of single hospital                       Cases (aged ≤75 years) with cerebral infarction and controls with a noraml carotid ultrascan scan and cerebral CT/MRI scan.                                                                                                                                                 IgM antibodies: ELISA techniques from serum samples.                                                                                                             Participants without any CMV infection                                                                                    Ischaemic stroke                                                     Diagnosis based on the 1995 National Cerebrovascular Disease Meeting standard for cerebral infarction, combined with a CT/MRI scan.

  Smieja, 2003\[[@pone.0206163.ref045]\]              Cohort          1993--1995 (recruitment)   Canada, multicentre RCT among patients with history of CVD                                           Patients ≥55 yr with blood samples (N = 3168/9541). Excluded those with;MI/ stroke 4 wk before study.                                                                                                                                                                       IgG antibodies: quantitative CMV IgG assay. Samples taken at baseline.                                                                                           Participants with no evidence of CMV infection                                                                            Stroke (secondary outcome)                                           Stroke was defined as a neurologic deficit lasting more than 24 hours

  Tarnacka, 2002\[[@pone.0206163.ref046]\]            Case-control    1998--1999                 Poland, patients with stroke consecutively admitted to neurology department.                         Cases were patients with stroke. Two control groups; "old" and "young," no clinical signs of infection/ other systemic diseases/ ischaemic stroke. All had increased values of serum IC concentrations                                                                      Elevated levels of IC containing anti-CMV antibodies; ELISA. Blood samples taken \<24 hrs and 7 to 30 days after stroke onset.                                   Elevated levels of IC not containing anti-CMV antibodies                                                                  Ischaemic stroke                                                     Stroke within 24 hrs after onset. CT imaging, sonography, echocardiography, and laboratory tests confirmed the diagnosis, established from history and examination

  Yi, 2008\[[@pone.0206163.ref047]\]                  Case-control    Unclear                    China, no further information                                                                        Cases (≥50 yrs) died of stroke, matched (age, sex) to controls with no cerebro-vascular disease, CMV-associated disease, immune suppression, or IgG for CMV.                                                                                                                DNA: immediate early (IE) and late (L) antigen in the intracranial arteries by PCR                                                                               Participants without CMV DNA                                                                                              Ischaemic stroke                                                     Patients died of ischaemic stroke.

  Zheng, 2016\[[@pone.0206163.ref048]\]               Case-control    2004--2014                 China, cohort study within a rural population with hypertension                                      Random sample of stroke cases (≥35 yr), matched (age \[1 yr\], sex, duration follow-up, hypertension stage) to controls without stroke. Patients with stroke and CAD at baseline excluded.                                                                                  DNA: PCR on blood samples taken at recruitment to original cohort study (prior to stroke).                                                                       Participants without CMV DNA. A negative result meant no DNA was detected.                                                Stroke                                                               First ever stroke during follow-up: evidence from imaging data extracted from patients medical records, and independently reviewed by the end-point assessment committee.

  Ziemann, 2016\[[@pone.0206163.ref049]\]             Cohort          2008                       Germany, trial in patients undergoing cardiac surgery, from single hospital                          Patients (≥18 yr) due for cardiac surgery: those with planned off-pump surgery excluded. 195/1178 (16.6%) patients excluded due to inadequate blood samples.                                                                                                                IgG antibodies: CMIA\                                                                                                                                            CMV seronegative participants                                                                                             Stroke                                                               Derived from the prospectively sampled cardiac surgery database. Defined as Stroke with Rankin grade\>1.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  DNA: PCR, arterial blood samples taken just before induction of anaesthesia.                                                                                                                                                                                                                                                                                    

  **CMV reactivation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Yen, 2016\[[@pone.0206163.ref009]\]                 Cohort          1998--2012                 Taiwan, National Health Insurance Research Database.                                                 Adults (≥15 yr) newly diagnosed with HIV, with no history of stroke or CMV infection.                                                                                                                                                                                       CMV end-organ disease: ICD-9 code (0.78.5 Cytomegaloviral disease) and prescription for an anti-CMV drug                                                         Participants without CMV end-organ disease                                                                                Primary: Any stroke\                                                 Hospitalisation or stroke from ICD-9 codes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary: ischaemic and haemorrhagic.                               

  **HHV6 infection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Fullerton, 2017\[[@pone.0206163.ref058]\]           Case-control    2009--2014                 United States,                                                                                       Children (aged 28 d to 18 yrs) with stroke and stroke-free trauma controls, frequency matched on age.                                                                                                                                                                       HHV6 DNA: MassTag PCR                                                                                                                                            Participants without HHV6 DNA                                                                                             Ischaemic stroke                                                     Acute diagnosis of ischemic stroke

  **VZV infection, serologically defined**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Asiki, 2015\[[@pone.0206163.ref059]\]               Case-control    Unclear                    Uganda, data from population based cohort study in rural setting                                     Adults stroke patients matched on sex and age to ≥4 controls without stroke. All participants had stored serum samples.                                                                                                                                                     IgG, IgM antibodies: quantitative indirect chemiluminescent immunoassays at/prior to stroke                                                                      IgG and IgM optical densities compared in cases versus controls                                                           Stroke                                                               Prevalent cases from clinical symptoms and deaths due to stroke by verbal autopsy.

  **VZV infection, clinically defined (varicella)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Askalan, 2001\[[@pone.0206163.ref060]\]             Cohort          1992--1999                 Canada, two hospitals.                                                                               Consecutive young children aged 6 mo to 10 yr with acute (or unders 3--6 mo follow-up for) stroke during the study period.                                                                                                                                                  Varicella 12 mo prior to stroke: parental interview                                                                                                              Patients without varicella                                                                                                Recurrent cerebral ischaemic events                                  TIAs and cerebral infarctions before or after the index AIS: parental interviews, radiographic films, health-record review

  Sébire, 1999\[[@pone.0206163.ref061]\]              Case-control    1985--1996                 France, referrals to single hospital for stroke treatment                                            Children with stroke matched to 4 healthy children (gender, age (±4 mo), site of residence)                                                                                                                                                                                 Varicella in the 9 mo prior to stroke; from an obligatory French health record                                                                                   Participants without varicella                                                                                            Ischaemic stroke                                                     First idiopathic arterial ischaemic stroke: angiograms and long-term clinical and angiographic follow-up

  Thomas, 2014\[[@pone.0206163.ref062]\]              SCCS            1990--2011                 UK, primary and secondary care records from 4 routinely collected databases                          Patients (any age) with first ever stroke/TIA and chickenpox during study period.                                                                                                                                                                                           Varicella: from Read codes. Exposed period: day after varicella and up to 1 yr after                                                                             \"Unexposed\" time: all follow-up time when individual not \"exposed\".                                                   Ischaemic stroke                                                     First stroke within study period; ascertained from Read codes.

  **Vaccination against herpesviruses**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Baxter, 2012\[[@pone.0206163.ref064]\]              Cohort          2006--2007                 United States, Kaiser Permanente Northern California (KPNC), health care system                      People (≥60 yr) vaccinated against HZ in routine medical care, with ≥180 days continuous KPNC membership after vaccination.                                                                                                                                                 HZ vaccination: in Kaiser Immunization Tracking system. Exposed period: 1--42 days after vaccination.                                                            Unexposed period: 91--180 days post vaccination.                                                                          Stroke                                                               Evidence of stroke (hospitalisations and emergency department visits) in 1--42 days following vaccination

  Kovac, 2018\[[@pone.0206163.ref063]\]               RCT                                        Multi-country, randomised placebo-controlled trial                                                   People(≥50 yr) randomised to placebo or HZ subunit vaccine. Excluded those with history of zoster, VZV vaccination, an immunosuppressive condition.                                                                                                                         HZ subunit vaccination                                                                                                                                           Placebo vaccination.                                                                                                      Stroke                                                               Clinical evidence of stroke (neurological deficit and change in consciousness) and either CT/MRI scan or no other sign of a disorder causing deficits

  Tseng, 2012\[[@pone.0206163.ref065]\]               SCCS            2007--2008                 United States, 8 managed-care systems taking part in Vaccine Safety Datalink Project                 Patients ≥50 yr receiving HZ vaccine who experienced stroke. 12 mo continuous membership was required, prior to first event.                                                                                                                                                HZ vaccination: medical records. Risk windows: 1--14 days, 15--28 days, 29--42 days, 1--42 days from vaccination.                                                Same length of time after a 30-day \"wash-out\" period following the risk window.                                         Stroke                                                               ICD-9 diagnosis codes from inpatients and emergency department records, with no code in the previous 12 mo

  Donahue, 2009\[[@pone.0206163.ref066]\]             Cohort          1991--2004                 United States, 8 managed-care systems taking part in Vaccine Safety Datalink Project                 Immunocompetent children (11mo to 17yr), ≥12 mo continuous enrolment, ≥1 encounter with site. Excluded those with infantile cerebral palsy stroke, or hemiplegia/ hemiparesis at ≤11 mo of age                                                                              Varicella vaccination: recorded in Vaccine Safety DataLink database.\                                                                                            1\) children without varicella vaccination; 2) exposed children: all other person time not classified as exposed.         Ischaemic stroke                                                     Primary or secondary coded diagnoses in inpatient settings using ICD-9 codes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Exposed period: 12-mo period following vaccination.                                                                                                                                                                                                                                                                                                             

  MacDonald, 2018\[[@pone.0206163.ref067]\]           Cohort          2006--2013                 Canada, administrative health databases                                                              Children receiving the varicella vaccination between 11 months and 23 months of age, and non-vaccinated children.                                                                                                                                                           Varicella vaccination: recorded in medical records.\                                                                                                             Children without varicella vaccination                                                                                    Ischaemic stroke                                                     ICD-10 codes recorded in hospital discharge database
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Exposed period: 12-mo period following vaccination.                                                                                                                                                                                                                                                                                                             

  **Multiple herpesviruses infections**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Al-Ghamdi, 2012\[[@pone.0206163.ref050]\]           Case- control   Unclear                    Saudi Arabia, a single hospital setting                                                              Patients with atherosclerotic vascular disease, matched (age, sex) to 15 healthy controls. Age not specified.                                                                                                                                                               HSV-1 and EBV IgG antibodies: ELISA kits. CMV IgG antibodies: bioelisa kit.                                                                                      Participants with a negative test result for exposures                                                                    Stroke                                                               Not reported

  Elkind, 2010\[[@pone.0206163.ref052]\]              Cohort          1993--2001                 US, community-based study to investigate epidemiology of stroke.                                     Adults \>39 yr, with no history of stroke, residing in household with a telephone, with blood samples available.                                                                                                                                                            CMV, HSV-1 and HSV-2: Enzyme-linked immunoassay used to measure IgG antibody titres against exposures.                                                           Participants with a negative test result for exposures                                                                    Stroke                                                               Defined using data from annual telephone follow-ups: symptoms and events consistent with stroke and classified by 2 neurologists.

  Elkind, 2016\[[@pone.0206163.ref051]\]              Case-control    2010--2014                 9 countries, Vascular Effects of Infection in Paediatric Stroke study                                All children (29 days to 18 yr) presenting to an included centre and enroled ≤3 wk of stroke, with an analysable blood sample.                                                                                                                                              IgG, IgM antibodies to HSV-1/2, CMV, EBV, VZV: blood samples ≤3 wk from stroke using ELISAs. Clinical infection, previous 6 mo from parent/guardian interview.   Participants without evidence of infection.                                                                               Ischaemic stroke                                                     Arterial ischaemic stroke: from clinical and imaging data by a trained specialist.

  Kis, 2007\[[@pone.0206163.ref053]\]                 Case-control    2003                       Hungary, patients hospitalised in 2003                                                               Cases (\<65 yr) admitted \<72 hr after stroke. Controls (\<76 yr) admitted for pain, without ischaemic stroke. Patients with history of MI, atrial fibrillation, valvular or myocardial heart disease excluded.                                                             CMV DNA: PCR\                                                                                                                                                    Participants without evidence of infection.                                                                               Ischaemic stroke                                                     First noncardiogenic ischaemic stroke: from clinical examinations and imaging techniques.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  IgG, IgA, IgM antibodies to HSV-1, CMV, EBV and HHV-6: ELISA, blood samples taken ≤1 wk from stroke.                                                                                                                                                                                                                                                            

  Li, 2005\[[@pone.0206163.ref054]\]                  Case-control    2001--2002                 China, department of neurology in a single hospital                                                  Cases (age unspecified) of stroke in progression. Excluded those with embolism and reversible ischaemic neurological deficit, cerebral haemorrhage, haemorrhagic infarction, \>5 yr history of severe disease. Controls were patients with non-cerebrovascular disease.     CMV, HSV-1 and HSV-2 IgM: dot immunogold labelling staining performed after stroke diagnosis (date unknown).                                                     Patients without herpesvirus IgM in blood                                                                                 Stroke in progression                                                Brain damage caused by an obstruction to the blood supply not preventable with convention treatment (e.g. urokinase for injection) within 72 hours from stroke onset. Confirmed with CT and/or MRI.

  Ozturk, 2013\[[@pone.0206163.ref055]\]              Case-control    Unclear                    Turkey, department of neurology in a single hospital                                                 Cases (\>40 yrs) were patients presenting with stroke \<24 hours of onset matched (age) to controls without ischaemic stroke or TIA. Patients with TIA, subarachnoidal hemorrhage, cerebral venous sinus occlusion with ischemic stroke due to head trauma were excluded.   CMV, EBV IgG: blood samples. CMV tested using ELISA and EBV tested using Viral capsid antigen                                                                    Patients without herpesvirus IgG in blood                                                                                 Ischaemic stroke                                                     Sudden focal or global cerebral impairment and at least one acute lesion. Computed tomography (CT) and magnetic resonance imaging (MRI) were performed in all patients during the first 24 hours

  Ridker, 1998\[[@pone.0206163.ref056]\]              Case-control    Unclear                    US, Physicians Health Study (RCT among male doctors with no history of MI, stroke or cancer).        Cases (age unspecified) were patients developing stroke/MI, matched (age, smoking, follow-up) to controls without MI or stroke. Participants with baseline blood samples included (14916/22071 \[68%\]).                                                                    CMV, HSV1/2 infection: plasma assayed using ELISA for presence or absence of IgG antibodies directed against HSV and CMV.                                        Seropositivity was compared in cases versus controls                                                                      Thromboembolic stroke                                                Hospital records and autopsy reports were used to confirm each diagnosis according to prespecified criteria

  Sealy-Jefferson, 2013\[[@pone.0206163.ref057]\]     Cohort          1998--2008                 US, cohort of Mexican Americans from the Sacramento Area Latino Study on Aging, community-dwelling   Participants from the cohort (60--101 yr at baseline) without a history of stroke at baseline.                                                                                                                                                                              CMV, HSV-1 and VZV IgG antibodies: solid-phase ELISA. Measured at baseline and follow-up visits                                                                  Seronegative to herpesviruses of interest.                                                                                Incident stroke                                                      Self-reported: determined at follow-up visits and semi-annual telephone calls. Fatal strokes identified from death certificates using the ICD-10 code 164.

  Yen, 2017\[[@pone.0206163.ref030]\]                 Cohort          2000--2012                 Taiwan, National Health Insurance Research Database.                                                 Patients (≥15 yr) with new HIV diagnosis. Patients who received a stroke diagnosis were excluded.                                                                                                                                                                           HZ and CMV disease after HIV diagnosis: ICD-9 codes from an inpatient setting or in ≥3 outpatient visits.                                                        Participants without diagnosis codes for HZ or CMV.                                                                       Stroke                                                               Patients hospitalised for stroke, identified through ICD-9 codes
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RCT = randomised controlled trial, SCCS = self-controlled case series, RR = risk (or rate) ratio, CI = confidence interval, transient ischaemic attack = TIA, HZ = herpes zoster, HZO = herpes zoster opthalmicus, ESRD = End-stage renal disease, CT = computerised tomography, MRI = magnetic resonance imaging, IBD = inflammatory bowel disease, SLE = systemic lupus erythematosus, MS = multiple sclerosis, RA = rheumatoid arthritis, HMO = health maintenance organization, GPRD = General Practice Research Database, THIN = The Health Improvement Network, CVD = cardiovascular disease, MEIA = micro-particle enzyme immunoassay technique, CMIA = chemiluminescent microparticle immunoassay, CAD = coronary artery disease, MI = myocardial infarction, ACE = angiotensin-converting--enzyme, IU = International Units, yr = year, mo = mo, wk = wk, hr = hour

\*Or Odds Ratio (OR) if specified.

10.1371/journal.pone.0206163.t002

###### Study results.

![](pone.0206163.t002){#pone.0206163.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, publication yr                        Design          Population size (N), follow-up time (yr)                                                                               Subjects with outcome \[or exposure for case-control studies\] (N, %)                                                                                                                                                                                                                                                                                                            Statistical analysis method used                                                               Main reported results                                                                                                                                                                                                                                                                                     Adjusted for
  --------------------------------------------------- --------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **VZV reactivation---herpes zoster**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Breuer, 2014                                        Cohort          Exposed = 106,601 Unexposed = 213,202\                                                                                 Stroke\                                                                                                                                                                                                                                                                                                                                                                          Cox proportional hazard models                                                                 Stroke: HR 1.02 (95% CI 0.98--1.07)                                                                                                                                                                                                                                                                       Matching variables (age, sex), obesity, smoking, history of cholesterol, hypertension, diabetes, IHD, atrial fibrillation, intermittent arterial claudication, carotid stenosis, heart disease
                                                                      Follow-up (median): 6.3 yr                                                                                             Exposed = 5,252 (2.46%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                             Unexposed = 2,727 (2.56%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Calabrese, 2017                                     Cohort          N = 43,527\                                                                                                            N = 680, 1.6%                                                                                                                                                                                                                                                                                                                                                                    Generalized linear models                                                                      0-90d: IRR 1.36 (1.10--1.68)\                                                                                                                                                                                                                                                                             Age, sex, race, diabetes mellitus, hypertension, atrial fibrillation, TIA, glucocorticoids.
                                                                      Follow-up: up to 7 yr (total 64,528.2 pyr)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             91-365d: IRR 1.18 (1.00--1.40)\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Baseline: 366-730days                                                                                                                                                                                                                                                                                     

  Hosamirudsari, 2018                                 Case-control    Cases = 105\                                                                                                           Cases: 24/105 (22.9%)\                                                                                                                                                                                                                                                                                                                                                           Logistic regression                                                                            OR, 5.84 (95% CI, 1.98‐ 8.23)                                                                                                                                                                                                                                                                             Age, sex, and hypertension.
                                                                      Controls = 105                                                                                                         Controls: 5/105 (4.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Kang, 2009                                          Cohort          Exposed = 7760\                                                                                                        Exposed = 133, 1.7%\                                                                                                                                                                                                                                                                                                                                                             Cox proportional hazard models                                                                 Risk of stroke during the 1-yr follow-up period: HR 1.31 (95% CI 1.06--1.60)                                                                                                                                                                                                                              Age, sex, income, urbanization, geographical location, hypertension, diabetes, renal disease, CHD, hyperlipidemia, atrial fibrillation, heart failure, heart valve/myocardium disease, and/or carotid/peripheral vascular disease
                                                                      Unexposed = 23,280\                                                                                                    Unexposed = 306, 1.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                      Follow-up: up to 1 year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Kim, 2017                                           Cohort          Exposed = 23,213\                                                                                                      Not reported                                                                                                                                                                                                                                                                                                                                                                     Not reported                                                                                   HR 1.35 (95% CI 1.18--1.54)                                                                                                                                                                                                                                                                               Age, sex, BMI, smoking, drinking, exercise, economic class, hypertension, diabetes, dyslipidemia, angina, TIA, heart failure, atrial fibrillation, heart disease, renal disease, carotid stenosis, peripheral vascular disease, liver disease, rheumatoid disease, inflammatory bowel disease, malignancy, transplantation, HIV, depression.
                                                                      Unexposed = 23,213\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                      Follow-up: up to 10 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Kwon, 2016                                          Cohort          Exposed = 77 781\                                                                                                      Crude incidence rate:\                                                                                                                                                                                                                                                                                                                                                           Time-updated Cox models                                                                        18--30 yrs: HR 1.52, 95% CI 1.26--1.83\                                                                                                                                                                                                                                                                   Age, gender, hypertension, hyperlipidaemia, IHD, diabetes, heart failure, peripheral vascular disease, atrial fibrillation or atrial flutter, chronic renal disease, valvular heart disease (time-updated)
                                                                      Unexposed = 695755\                                                                                                    9.8/1000 py                                                                                                                                                                                                                                                                                                                                                                                                                                                                     30--40 yrs: HR 1.34, 95% CI 1.19--1.51\                                                                                                                                                                                                                                                                   
                                                                      Follow-up: up to 11 yr (total 7,770,699 years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         40--50 yrs: HR 1.19, 95% CI 1.12--1.29\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             50--60 yrs: HR 1.12, 95% CI 1.06--1.19\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             60--70 yrs: HR 1.14, 95% CI 1.08--1.20\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \>70 yrs: HR 1.14, 95% CI 1.06--1.23                                                                                                                                                                                                                                                                      

  Langan, 2014                                        SCCS            N = 6584\                                                                                                              wk 1--4: n = 90\                                                                                                                                                                                                                                                                                                                                                                 Conditional Poisson regression                                                                 wk 1--4: IR 1.63 (1.32--2.02)\                                                                                                                                                                                                                                                                            Age and time-invariant confounders
                                                                      Follow-up (median): 12.5 yr (IQR, 8.7--17.1).                                                                          wk 5--12: n = 149\                                                                                                                                                                                                                                                                                                                                                                                                                                                              wk 5--12: IR 1.42 (1.21--1.68)\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                             wk 13--26: n = 215\                                                                                                                                                                                                                                                                                                                                                                                                                                                             wk 13--26: IR 1.23 (1.07--1.42)\                                                                                                                                                                                                                                                                          
                                                                                                                                                                                             wk 27--52: n = 303                                                                                                                                                                                                                                                                                                                                                                                                                                                              wk 27--52: IR 0.99 (0.88--1.12)                                                                                                                                                                                                                                                                           

  Liao, 2017                                          Cohort          HZ patients = 2744\                                                                                                    Exposed = 116, 4.2%\                                                                                                                                                                                                                                                                                                                                                             Cox proportional hazard models                                                                 0-90d: HR 2.30 (95%CI 1.13--4.69)\                                                                                                                                                                                                                                                                        Age, sex, atrial fibrillation, CKD, COPD, diabetes mellitus, dyslipidemia, and hypertension
                                                                      Non HZ patients = 5475                                                                                                 Unexposed = 186, 3.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                           91-365d: HR 1.05 (95%CI 0.58--1.90)\                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             366-730d: HR 1.16 (95%CI 0.70--1.92)\                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \>730d: HR 1.18 (95%CI 0.86--1.64)                                                                                                                                                                                                                                                                        

  Lin, 2010                                           Cohort          Exposed = 658\                                                                                                         Exposed = 53, 8.1%\                                                                                                                                                                                                                                                                                                                                                              Cox proportional hazard\                                                                       \                                                                                                                                                                                                                                                                                                         Age, gender, hypertension, diabetes, hyperlipidemia, CHD, chronic rheumatic heart disease, other forms of heart disease, and medication habits
                                                                      Unexposed = 1974\                                                                                                      Unexposed = 33, 1.7%                                                                                                                                                                                                                                                                                                                                                             regressions                                                                                    HR 4.52 (95% CI 2.45--8.33)                                                                                                                                                                                                                                                                               
                                                                      Follow-up: up to 1 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Minassian, 2015                                     SCCS            N = 42,954\                                                                                                            Baseline: n = 32179\                                                                                                                                                                                                                                                                                                                                                             Conditional Poisson regression                                                                 wk 1: IR 2.37, 95% CI 2.17--2.59\                                                                                                                                                                                                                                                                         Age in 2-yr age bands and time-invariant confounders
                                                                      Follow-up (median): 5 yr (IQR: 4--5 yr)                                                                                wk 1: n = 499\                                                                                                                                                                                                                                                                                                                                                                                                                                                                  wk 2--4: IR 1.55, 95% CI 1.46--1.66\                                                                                                                                                                                                                                                                      
                                                                                                                                                                                             wk 2--4: n = 967\                                                                                                                                                                                                                                                                                                                                                                                                                                                               wk 5--12: IR 1.17, 95% CI 1.11--1.22\                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             wk 5--12: n = 1841\                                                                                                                                                                                                                                                                                                                                                                                                                                                             wk 13--26: IR 1.03, 95% CI 0.99--1.07\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                             wk 13--26: n = 2588\                                                                                                                                                                                                                                                                                                                                                                                                                                                            wk 27--52: IR 1.00, 95% CI 0.96--1.03                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             wk 27--52: n = 3981                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Patterson, 2018                                     Cohort          Exposed = 23,339\                                                                                                      Exposed = 141, 6.0%\                                                                                                                                                                                                                                                                                                                                                             Multivariate Poisson models                                                                    IRR 1.40 (95%CI 0.93--2.11)                                                                                                                                                                                                                                                                               Sociodemographic and clinical factors, including smoking status and BMI
                                                                      Unexposed = 46,378\                                                                                                    Unexposed = 262, 5.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                      Follow-up: up to 10 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Schink, 2016                                        SCCS            N = 6,035\                                                                                                             \                                                                                                                                                                                                                                                                                                                                                                                Log-linear Poisson model                                                                       \<2 wk: 1.30 (1.00--1.68)\                                                                                                                                                                                                                                                                                Age
                                                                      Followup time (mean): 5.6 yr                                                                                           3 mo following zoster: N = 352                                                                                                                                                                                                                                                                                                                                                                                                                                                  wk 3--4: IRR 1.52 (1.20--1.91)\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             mo 2--3: IRR 1.24 (1.08--1.42)\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             mo 4--6: IRR 1.09 (0.97--1.24)\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             mo 7--12: IRR 0.96 (0.87--1.06)                                                                                                                                                                                                                                                                           

  Sreenivasan, 2013                                   Cohort          N = 4,503,054\                                                                                                         Overall:\                                                                                                                                                                                                                                                                                                                                                                        Poisson regression                                                                             \< 14 days since HZ: IRR 2.27 (95%CI 1.83--2.82)\                                                                                                                                                                                                                                                         Age, sex, calendar period.
                                                                      Exposed: 117926\                                                                                                       N = 230341, 5.0%.\                                                                                                                                                                                                                                                                                                                                                                                                                                                              14 days-1 yr: IRR 1.17 (95%CI 1.09--1.24)\                                                                                                                                                                                                                                                                
                                                                      Follow-up: up to 14 years                                                                                              Exposed: 4876/117926, 4.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                      \> 1 yr: IRR 1.05 (95%CI 1.02--1.09)                                                                                                                                                                                                                                                                      

  Sundström, 2015                                     Cohort          General population = 4,707,885\                                                                                        Exposed = 111\                                                                                                                                                                                                                                                                                                                                                                   Poisson regression                                                                             IRR 1.34 (95% CI 1.12--1.62)                                                                                                                                                                                                                                                                              Age and sex.
                                                                      Exposed = 13296\                                                                                                       General population = unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                      All followed for 1-yr.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Tseng, 2011                                         Cohort          Not reported\                                                                                                          Exposed = 227\                                                                                                                                                                                                                                                                                                                                                                   Not reported                                                                                   HR 1.11 (95% CI 0.92 to 1.33)                                                                                                                                                                                                                                                                             Matching factors (age and sex), race, heart diseases, diabetes, lung, kidney, liver disease, hypertension, dementia
                                                                      Follow-up: up to 4 years                                                                                               Unexposed = 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Yawn, 2016                                          Cohort          Exposed = 4478Unexposed = 16,800Follow-up (mean): 7.1 yr (range 0--28.6 yr)                                            EverExposed = 562, 12.6%Unexposed = 1844, 11.0%                                                                                                                                                                                                                                                                                                                                  Logistic regression                                                                            OR (95% CI):3 mo: 1.53 (1.01--2.33)6 mo: 1.28 (0.91--1.80)1 yr: 1.04 (0.79--1.36)3 yr: 1.02 (0.86--1.22)                                                                                                                                                                                                  3 mo: Age, vasculopathy, arrhythmias.6 mo: Age, vasculopathy, hypertension.1 yr: Age, vasculopathy, hypertension, CAD, dyslipidemia.3 yr: Age, gender, hypertension, CAD, dyslipidemia, depression, vasculopathy.

  **CMV infection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Coles, 2003                                         Case-cohort     Stroke cases = 119\                                                                                                    \                                                                                                                                                                                                                                                                                                                                                                                Cox proportional hazards regression                                                            CMV IgG: RR 0.93 (95% CI 0.46, 1.89)\                                                                                                                                                                                                                                                                     Age, gender, BMI, cholesterol, triglycerides, diabetes, haemoglobin, treatment for hypertension, systolic blood pressure and smoking.
                                                                      Random sub-cohort = 451\                                                                                               CMV IgG: Stroke cases: 84.9%; Random sub-cohort: 85.4%\                                                                                                                                                                                                                                                                                                                                                                                                                         CMV IgG high titre: RR 0.78 (95% CI 0.49, 1.23)                                                                                                                                                                                                                                                           
                                                                      Follow-up time: up to 3 years                                                                                          High level CMV IgG: Stroke cases: 40.3%; Random sub-cohort: 38.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Fagerberg, 1999                                     Cohort          N = 152\                                                                                                               Not reported                                                                                                                                                                                                                                                                                                                                                                     Poisson regression                                                                             Relative Risk of High Titres of Antibodies to CMV for Stroke: RR 1.04 (95% CI 0.13--8.51)                                                                                                                                                                                                                 Smoking, presence of previous cardiovascular disease, group allocation in the underlying multiple risk factor intervention study (multifactorial risk factor intervention or usual care)
                                                                      Follow-up (median): 6.5 yr (range 0.2--7.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  González-Quijada, 2015                              Case-control    Cases = 111\                                                                                                           Cases: Seropositive CMV = 98, 95.1%; High-titre IgG antibodies = 37, 35.0%\                                                                                                                                                                                                                                                                                                      Logistic regression                                                                            High-titre IgG antibodies (top quartile) against CMV (OR 2.1, 95% CI 1.3 to 3.5)                                                                                                                                                                                                                          Adjusted for sex, age \>81 yr, hypertension, dyslipidaemia, smoking habits, diabetes, cardioembolic focus, other vascular diseases, white blood cells, and C-reactive protein.
                                                                      Controls = 523                                                                                                         Controls: Seropositive CMV = 455, 92.9%; High-titre IgG antibodies = 109, 22.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Huang, 2012                                         Case-control    Cases = 200\                                                                                                           CMV DNA\                                                                                                                                                                                                                                                                                                                                                                         Logistic regression                                                                            Odds of stroke associated with CMV DNA\                                                                                                                                                                                                                                                                   Age, sex, BMI, hypertension and smoking
                                                                      Controls = 200                                                                                                         Cases (stroke) = 110, 55%\                                                                                                                                                                                                                                                                                                                                                                                                                                                      Any stroke: OR 3.98 (95%CI 2.50--6.32)                                                                                                                                                                                                                                                                    
                                                                                                                                                                                             Controls = 47, 23.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Kenina, 2010                                        Case-control    Cases = 102\                                                                                                           CMV seropositivity\                                                                                                                                                                                                                                                                                                                                                              None                                                                                           OR for CMV seropositivity: OR 0.90 (95% CI 0.22--3.66)\                                                                                                                                                                                                                                                   None
                                                                      Controls = 48                                                                                                          Cases = 95/102, 93%; Controls = 45/48, 94%\                                                                                                                                                                                                                                                                                                                                                                                                                                     \[calculated by review authors\]                                                                                                                                                                                                                                                                          
                                                                                                                                                                                             Mean CMV IgG antibody levels (IU/ml)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             Cases: 6.43 ± 2.6; Controls: 5.83 ± 2.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Oliveras, 2003                                      Cohort          N = 403\                                                                                                               Total: N = 19 (7.97%) at 10 yr follow-up. Denominator inferred to be 238\                                                                                                                                                                                                                                                                                                        Chi-squared test                                                                               RR 0.60 (95% CI 0.03--10.41)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                                       None
                                                                      Time from RT until stroke = 49.3 mo (SD = 25.6 mo)                                                                     Exposed: 0/16, 0%\                                                                                                                                                                                                                                                                                                                                                                                                                                                              \[calculated by review authors\]                                                                                                                                                                                                                                                                          
                                                                                                                                                                                             Unexposed: 19/387, 4.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Shen, 2011                                          Case-control    Cases = 81\                                                                                                            Cases: 40/81 (49.4%)\                                                                                                                                                                                                                                                                                                                                                            Chi-squared test                                                                               OR 4.51 (95% CI: 2.16--9.40)                                                                                                                                                                                                                                                                              None
                                                                      Controls = 72                                                                                                          Controls: 13/72 (17.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Smieja, 2003                                        Cohort          N = 3168\                                                                                                              Overall: 107/3164 (3.4%)                                                                                                                                                                                                                                                                                                                                                         Cox proportional hazards                                                                       HR 0.93 (95% CI 0.61, 1.42)                                                                                                                                                                                                                                                                               Age, sex, smoking status, ramipril randomization, diabetes mellitus, hypertension, and history of hypercholesterolemia
                                                                      Follow-up (mean) = 4.5 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Tarnacka, 2002                                      Case-control    Cases: n = 56\                                                                                                         IC Containing Anti-CMV Antibodies\                                                                                                                                                                                                                                                                                                                                               Not reported                                                                                   Increased levels of serum CMV-specific IC were connected with increased risk of stroke incidence (odds ratio, 7.60; 95% CI, 3.21 to 17.96)[^3^](#t002fn004){ref-type="table-fn"}.                                                                                                                         None reported
                                                                      \"Old\" controls: n = 53\                                                                                              Cases: 41/55 (74.5%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                      \"Young\" controls: n = 57                                                                                             Old controls: 11/42 (26.2%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                             Young controls: 23/57 (40.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Yi, 2008                                            Case-control    Cases = 35\                                                                                                            CMV IE genes/proteins\                                                                                                                                                                                                                                                                                                                                                           Chi-squared tests                                                                              CMV IE genes/protein: 3.50 (1.08--11.29)\                                                                                                                                                                                                                                                                 No adjustments made---matched on age and sex
                                                                      Controls = 20                                                                                                          Cases: 21/35 (60.0%), Controls: 6/20 (30.0%)\                                                                                                                                                                                                                                                                                                                                                                                                                                   CMV L genes/protein: 1.00 (0.25--3.95)\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                             CMV L genes/proteins\                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[calculated by review authors---matching not accounted for\]                                                                                                                                                                                                                                             
                                                                                                                                                                                             Cases: 7/35 (20.0%), Controls: 4/20 (20.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Zheng, 2016                                         Case-control    Controls = 300\                                                                                                        Proportion of patients with CMV DNA\                                                                                                                                                                                                                                                                                                                                             Conditional logistic regression                                                                OR 1.46 (95% CI, 1.00--2.14)                                                                                                                                                                                                                                                                              Matching factors (age, gender, follow-up, stage of hypertension), pulse rate, BMI, LDL-C, HDL-C, triglycerides, fasting glucose, smoking, drinking, antihypertensives, statins, antiplatelet agents, and anticoagulants
                                                                      Cases = 300\                                                                                                           Cases: 38/300 (12.7%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                      Follow-up (median): 8.4 yr                                                                                             Controls: 17/300 (5.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Ziemann, 2016                                       Cohort          N = 983\                                                                                                               CMV seropositive: n = 8/618 (1%)\                                                                                                                                                                                                                                                                                                                                                Chi-square test                                                                                Risk ratio: 0.79 (95% CI 0.28--2.25)\                                                                                                                                                                                                                                                                     None reported
                                                                      Follow-up: unclear                                                                                                     CMV seronegative: n = 6/365 (2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                \[calculated by review authors\]                                                                                                                                                                                                                                                                          

  **CMV reactivation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Yen, 2016                                           Cohort          Total: N = 22,581Exposed = 439, follow-up time 6.1 yr (SD = 3.8)Unexposed = 22,142, follow-up time 4.8 yr (SD = 3.7)   Exposed: 17/439 (3.2%)Unexposed: 211/22,142 (0.7%)                                                                                                                                                                                                                                                                                                                               Cox proportional-hazards model                                                                 HR, 3.07; 95% CI, 1.70 to 5.55                                                                                                                                                                                                                                                                            Age, sex, diabetes, CKD, hypertension, CHD, cancer, dyslipidaemia, tuberculosis infection, disseminated Mycobacterium avium complex infection, pneumonia, meningitis, Penicillium marneffei infection, toxoplasma encephalitis, candidiasis, HZ and HAART.

  **HHV6 infection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Fullerton, 2017                                     Case-control    Cases = 161\                                                                                                           Cases: 2/161 (1.2%)\                                                                                                                                                                                                                                                                                                                                                             Not reported                                                                                   OR 1.07 (95% CI 0.05--22.7)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                                        No adjustments made---matched on age
                                                                      Controls = 34                                                                                                          Controls: 0/34 (0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[calculated by review authors\]                                                                                                                                                                                                                                                                          

  **VZV infection, serologically defined**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Asiki, 2015                                         Case-control    Cases = 31\                                                                                                            All participants had detectable IgG and IgM antibodies against VZV                                                                                                                                                                                                                                                                                                               Mann--Whitney two-sample test                                                                  Median VZV IgG (IQR) at index date\                                                                                                                                                                                                                                                                       No adjustments made---matched on age and sex
                                                                      Controls = 132                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Cases: 2.06 (1.45--2.42) Controls: 1.91 (1.52--2.26); P value: 0.47\                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Median VZV IgM (IQR) at index date\                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Cases: 0.32 (0.19--0.43) Controls: 0.29 (0.20--0.50); P value: 0.69                                                                                                                                                                                                                                       

  **VZV infection, clinically defined (varicella)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Askalan, 2001                                       Cohort          \                                                                                                                      Exposed: 10/22 (45%)\                                                                                                                                                                                                                                                                                                                                                            Not reported                                                                                   OR 4.1 (95% CI 1.3--12.9)\                                                                                                                                                                                                                                                                                No adjustments made
                                                                      Exposed = 22\                                                                                                          Unexposed: 8/48 (17%)                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[calculated by review authors\]                                                                                                                                                                                                                                                                          
                                                                      Unexposed = 48\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                      Follow-up: up to 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Sébire, 1999                                        Case-control    Cases = 11\                                                                                                            Cases: 7/11 (64%)\                                                                                                                                                                                                                                                                                                                                                               Fisher's exact test                                                                            OR: 17.5 (95% CI 3.53--86.83)\                                                                                                                                                                                                                                                                            No adjustments made---matched on age, sex and site of residence
                                                                      Controls = 44                                                                                                          Controls: 4/44 (9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[Calculated by review authors\]                                                                                                                                                                                                                                                                          

  Thomas, 2014                                        SCCS            \                                                                                                                      \                                                                                                                                                                                                                                                                                                                                                                                Conditional Poisson regression for individual database, meta-analysis for combined databases   Children (fixed effects meta-analysis)\                                                                                                                                                                                                                                                                   Age (in 5-yr bands).
                                                                      Children = 60, median follow-up 6.6 yr (IQR 4.7--11.7)\                                                                Children = 49\                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0-6mo: IR 4.07 (95% CI 1.96--8.45)\                                                                                                                                                                                                                                                                       
                                                                      Adults = 500, median follow-up 14.2 yr (IQR 9.9--18.8)                                                                 0--6 mo: 12; 7--12 mo: 6; Unexposed period: 31\                                                                                                                                                                                                                                                                                                                                                                                                                                 7--12 mo: IR 2.37 (95% CI 0.93--6.06)\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                             Adults = 241\                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Adults (random effects meta-analysis)\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                             0--6 mo: 20; 7--12 mo: 11; Unexposed period: 210                                                                                                                                                                                                                                                                                                                                                                                                                                0--6 mo: IR 2.13 (95% CI 1.05--4.36)\                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             7--12 mo: IR 1.23 (95% CI 0.66--2.30)                                                                                                                                                                                                                                                                     

  **Vaccination against herpesviruses**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Baxter, 2012                                        Cohort          N = 29,010\                                                                                                            N = 193, with 38 confirmed after case review by specialists (risk period of the stroke unknown)                                                                                                                                                                                                                                                                                  Exact conditional method                                                                       RR = 0.91; 95% CI: 0.43--1.81                                                                                                                                                                                                                                                                             None (design accounts for within person confounding)
                                                                      Cohort followed for 180d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Kovac, 2018                                         RCT             Vaccinated group: 13,881\                                                                                              Vaccinated group: 0(0%)\                                                                                                                                                                                                                                                                                                                                                         None                                                                                           OR: 1.01 (95% CI 0.02--51.0)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                                       None (randomised design accounts for confounders)
                                                                      Placebo group: 14,035\                                                                                                 Placebo group: 0 (0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[Calculated by review authors\]                                                                                                                                                                                                                                                                          
                                                                      Follow-up (mean): 3.9 ± 0.7 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Tseng, 2012                                         SCCS            Days 1--14: n = 167\                                                                                                   No. of cases in risk window/control window.\                                                                                                                                                                                                                                                                                                                                     Conditional Poisson regression                                                                 \                                                                                                                                                                                                                                                                                                         None (design accounts for within person confounding)
                                                                      Days 15--28: n = 147\                                                                                                  Days 1--14: 81/86\                                                                                                                                                                                                                                                                                                                                                                                                                                                              Days 1--14: RR 0.94 (95% CI 0.70--1.28)\                                                                                                                                                                                                                                                                  
                                                                      Days 29--42: n = 169\                                                                                                  Days 15--28: 74/73\                                                                                                                                                                                                                                                                                                                                                                                                                                                             Days 15--28: RR 1.03 (95% CI 0.74--1.42)\                                                                                                                                                                                                                                                                 
                                                                      Days 1--42: n = 468\                                                                                                   Days 29--42: 83/86\                                                                                                                                                                                                                                                                                                                                                                                                                                                             Days 29--42: RR 0.97 (95% CI 0.71--1.30)\                                                                                                                                                                                                                                                                 
                                                                      Follow-up: 42 days                                                                                                     Days 1--42: 233/235                                                                                                                                                                                                                                                                                                                                                                                                                                                             Days 1--42: RR 0.99 (95% CI 0.83--1.19)                                                                                                                                                                                                                                                                   

  Donahue, 2009                                       Cohort          N = 3240473\                                                                                                           Vaccinated: n = 39 (0.003%) (8 occurred in 12 mo risk period following vaccination)\                                                                                                                                                                                                                                                                                             \                                                                                              adjHR (95% CI) after vaccination\                                                                                                                                                                                                                                                                         Gender, calendar time, geographical site, cardiac disease, rheumatic heart disease and endocarditis, CVD, sickle cell disease, conditions predisposing to vasculopathy, coagulation abnormalities, and diseases leading to a hypercoagulable state.
                                                                      Vaccinated: 1,142,920\                                                                                                 Unvaccinated: n = 164 (0.008%)                                                                                                                                                                                                                                                                                                                                                   Cox regression                                                                                 0 to \<1 mo: 1.1 (0.1--9.2)\                                                                                                                                                                                                                                                                              
                                                                      Unvaccinated: 2,097,553\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1 to \<3 mo: 0.7 (0.1--5.7)\                                                                                                                                                                                                                                                                              
                                                                      Follow-up: up to 13 yr (total py 17.2 million)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3 to \<6 mo: 1.3 (0.3--5.6)\                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             6 to \<9 mo: 1.3 (0.4--4.9)\                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             9 to \<12 mon: 0.4 (0.0--3.2)                                                                                                                                                                                                                                                                             

  MacDonald, 2018                                     Cohort          \                                                                                                                      Vaccinated group: 25 (0.01%)\                                                                                                                                                                                                                                                                                                                                                    Cox proportional hazards model                                                                 HR 1.6 (95% CI 0.7--3.7)                                                                                                                                                                                                                                                                                  Moyamoya disease, Sickle cell disease, Congenital heart disease, Meningitis, Severe sepsis, Intracranial injury, Varicella infection, AIS history before 11 months of age.
                                                                      Vaccinated: 325,729\                                                                                                   Unvaccinated group: 6 (0.01%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                      Unvaccinated: 43,263\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                      Follow-up: 1 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Multiple herpesviruses infections**               ** **           ** **                                                                                                                  ** **                                                                                                                                                                                                                                                                                                                                                                            ** **                                                                                          ** **                                                                                                                                                                                                                                                                                                     

  Al-Ghamdi, 2012                                     Case- control   Cases = 20\                                                                                                            HSV-1---Cases: n = 20, 100%; controls n = 14, 93.9%\                                                                                                                                                                                                                                                                                                                             Chi-squared test                                                                               HSV-1: OR 2.86 (95% CI 0.09--91.16)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                                No adjustments made---matched on age and sex
                                                                      Controls = 15                                                                                                          CMV---Cases: n = 9,45%; controls n = 3, 20%.\                                                                                                                                                                                                                                                                                                                                                                                                                                   CMV: OR 3.27 (95% CI 0.70--15.29)\                                                                                                                                                                                                                                                                        
                                                                                                                                                                                             EBV---Cases: n = 18, 90%; controls n = 14, 93.3%.                                                                                                                                                                                                                                                                                                                                                                                                                               EBV: OR 0.64 (95% CI 0.05--7.83)\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[calculated by review author\]                                                                                                                                                                                                                                                                           

  Elkind, 2010                                        Cohort          N = 1625, Median follow-up 7.6 yr (IQR: 6.4--9.0)\                                                                     Overall: 67 strokes (56 ischaemic)                                                                                                                                                                                                                                                                                                                                               Cox proportional hazards models                                                                CMV IgG: HR 2.19 (95%CI 0.84--5.70)\                                                                                                                                                                                                                                                                      Age, sex, ethnicity, education, systolic blood pressure, cholesterol level, alcohol use, smoking status, waist circumference, physical activity, and CAD
                                                                      CMV = 1388 (85.4%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    HSV-1 IgG: HR 1.35 (95%CI 0.59--3.07)\                                                                                                                                                                                                                                                                    
                                                                      HSV-1 = 1402 (86.3%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  HSV-2 IgG: HR 1.59 (95%CI 0.91--2.76)                                                                                                                                                                                                                                                                     
                                                                      HSV-2 = 928 (57.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Elkind, 2016                                        Case-control    Cases = 326Controls = 115                                                                                              Past infection:HSV-1/2: Cases: 53, 16.3%; controls 24, 20.9% CMV: Cases: 95, 29.1%; controls 42, 36.5% EBV: Cases: 176, 54.0%; controls 58, 50.4% VZV: Cases: 182, 55.8%; controls 68, 59.1%Acute Infection:HSV-1/2: Cases: 80, 24.5%; controls 19, 16.5% CMV: Cases: 18, 5.5%; controls 2, 1.7% EBV: Cases: 4, 1.2%; controls 1, 0.9% VZV: Cases: 37, 11.3%; controls 3, 2.6%   Logistic regression                                                                            Past infection:HSV-1/2: OR 0.78 (95% CI 0.45--1.35)CMV: OR 0.74 (95% CI 0.47--1.17)EBV: OR 1.26 (95% CI 0.82--1.95)VZV: OR 0.93 (95% CI 0.60--1.44)Acute Infection:HSV-1/2: OR 1.68 (95% CI 0.98--3.00)CMV: OR 2.85 (95% CI 0.79--18.2)EBV: OR 1.44 (95% CI 0.21--28.4)VZV: OR 4.43 (95% CI 1.55--18.7)   Age.\*Age, Race, Residence (urban, rural, suburban), country income (low/middle or high income)

  Kis, 2007                                           Case-control    Cases = 59\                                                                                                            CMV DNA---Cases: n = 1, 1.7%; Controls: n = 0, 0%\                                                                                                                                                                                                                                                                                                                               Logistic regression                                                                            Highest tertile v. lower two tertiles\                                                                                                                                                                                                                                                                    Age, gender, smoking, alcohol, lipid, hypertension, sedimentation rate
                                                                      Controls = 52                                                                                                          CMV IgM---Cases: n = 0, 0%; Controls: n = 0, 0%\                                                                                                                                                                                                                                                                                                                                                                                                                                CMV IgG†: OR 4.95 (95% CI 1.38--17.80)\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                             CMV IgG---Cases: n = 26, 44.1%; Controls: 11, 21.2%\                                                                                                                                                                                                                                                                                                                                                                                                                            HSV-1 IgA‡: OR 3.69 (95% CI 1.47--9.21)\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                             HSV-1 IgA---Cases: n = 24, 40.7%; Controls: n = 8, 15.7%\                                                                                                                                                                                                                                                                                                                                                                                                                       \[below calculated by review authors---unadjusted\]\                                                                                                                                                                                                                                                      
                                                                                                                                                                                             HSV-1 IgG---Cases: n = 23, 39.0%; Controls: n = 14, 27.4%\                                                                                                                                                                                                                                                                                                                                                                                                                      CMV DNA: OR 2.69 (95% CI 0.11--67.53)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                              
                                                                                                                                                                                             EBV IgG---Cases: n = 22, 37.3%; Controls: n = 15, 28.8%\                                                                                                                                                                                                                                                                                                                                                                                                                        CMV IgM: OR 0.88 (95% CI 0.01--45.2)[^1^](#t002fn002){ref-type="table-fn"}\                                                                                                                                                                                                                               
                                                                                                                                                                                             HHV-6 IgG---Cases: n = 19, 32.2%; Controls; n = 18, 34.6%                                                                                                                                                                                                                                                                                                                                                                                                                       HSV1 IgG: OR 1.73 (95% CI 0.77--3.88)\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             EBV IgG: OR 1.46 (95% CI 0.66--3.26)\                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             HHV-6 IgG: OR 0.90 (0.41--1.98)                                                                                                                                                                                                                                                                           

  Li, 2005                                            Case-control    Cases = 47\                                                                                                            CMV: Cases: 20/47 (43%[^2^](#t002fn003){ref-type="table-fn"}); Controls: 20/193 (10%)\                                                                                                                                                                                                                                                                                           Chi-squared test                                                                               CMV: OR 6.41 (95% CI 3.05--13.44)\                                                                                                                                                                                                                                                                        None
                                                                      Controls = 193                                                                                                         HSV-1: Cases: 6/47 (13%[^2^](#t002fn003){ref-type="table-fn"}); Controls: 7/193 (4%)\                                                                                                                                                                                                                                                                                                                                                                                           HSV-1: OR 3.89 (95% CI 1.24--12.18)\                                                                                                                                                                                                                                                                      
                                                                                                                                                                                             HSV-2: Cases: 7/47 (15%[^2^](#t002fn003){ref-type="table-fn"}); Controls: 22/193 (11%)                                                                                                                                                                                                                                                                                                                                                                                          HSV-2: OR 1.36 (95% CI 0.54--3.40)\                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[calculated by review authors\]                                                                                                                                                                                                                                                                          

  Ozturk, 2013                                        Case-control    Cases = 72\                                                                                                            CMV: Cases: n = 71/72 (98.6%); Controls: n = 58/60 (96.7%)\                                                                                                                                                                                                                                                                                                                      Logistic regression                                                                            CMV: OR 2.45 (95% CI 0.22--27.68)\                                                                                                                                                                                                                                                                        No adjustments made---matched on age
                                                                      Controls = 60                                                                                                          EBV: Cases: n = 41/72 (56.9%); Controls: n = 29/60 (48.3%)                                                                                                                                                                                                                                                                                                                                                                                                                      EBV: OR 1.41 (95% CI 0.71--2.81)\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[calculated by review authors\]                                                                                                                                                                                                                                                                          

  Ridker, 1998                                        Case-control    Cases = 643 (only 271 were stroke patients)\                                                                           HSV-1/2: Stroke cases: n = 271 (73.6%); Controls: n = 643 (69.4%)\                                                                                                                                                                                                                                                                                                               Conditional logistic regression                                                                HSV-1/2: RR 1.0 (95% CI 0.7--1.5)\                                                                                                                                                                                                                                                                        Matching factors (age, smoking, follow-up), treatment assignment, BMI, hypertension, hypercholesterolemia, diabetes, and a family history of premature atherosclerosis.
                                                                      Controls = 643                                                                                                         CMV: Stroke cases: n = 271 (65.3%); Controls: n = 643 (70.2%)                                                                                                                                                                                                                                                                                                                                                                                                                   CMV: RR 0.67 (95% CI 0.4--1.0)                                                                                                                                                                                                                                                                            

  Sealy-Jefferson, 2013                               Cohort          Total N = 1621.\                                                                                                       CMV: Exposed: 97 (9.9%); Unexposed: 67 (10.4%)\                                                                                                                                                                                                                                                                                                                                  Discrete-time logistic regression                                                              IgG in the 75th versus 25th percentile\                                                                                                                                                                                                                                                                   Hypertension, diabetes, hyperlipidaemia, smoking, atrial fibrillation, BMI, coronary heart disease and/or peripheral artery disease, education, age and gender.
                                                                      CMV: 979 (60.4%)\                                                                                                      VZV: Exposed: 36 (12.0%); Unexposed: 128 (9.7%)\                                                                                                                                                                                                                                                                                                                                                                                                                                CMV: OR 0.81 (95% CI 0.58, 1.12)\                                                                                                                                                                                                                                                                         
                                                                      VZV: 299 (18.4%)\                                                                                                      HSV-1: Exposed: 94 (9.3%); Unexposed: 70 (11.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                VZV: OR 0.93 (95% CI 0.71, 1.20)\                                                                                                                                                                                                                                                                         
                                                                      HSV-1: 1014 (62.6%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   HSV-1: OR 0.77 (95% CI 0.56, 1.07)                                                                                                                                                                                                                                                                        
                                                                      Folow-up: up to 10 yr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Yen, 2017                                           Cohort          \                                                                                                                      CMV infection: 10/311 (3.2%); No CMV infection 242/21064 (1.2%)\                                                                                                                                                                                                                                                                                                                 Cox regression model                                                                           CMV infection: HR 2.71 (95% CI 1.34 to 5.49)\                                                                                                                                                                                                                                                             Age, sex, diabetes, chronic kidney disease, hypertension, coronary heart disease, cancer, dyslipidemia, and systemic lupus erythematosus and HAART.
                                                                      HIV patients: N = 21,375. Mean follow-up time 4.65 yr (SD 3.36).                                                       HZ: 238/20020 (1.2%); No HZ: 14/1355 (1.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                     HZ: HR 0.80 (95% CI 0.46 to 1.40)                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RCT = randomised controlled trial, SCCS = self-controlled case series, RR = risk (or rate) ratio, CI = confidence interval, transient ischaemic attack = TIA, COPD = chronic obstructive pulmonary disorder, CKD = chronic kidney disease, HZ = herpes zoster, HZO = herpes zoster opthalmicus, ESRD = End-stage renal disease, CT = computerised tomography, MRI = magnetic resonance imaging, yr = year, mo = mo, wk = wk, pyr = person years

^1^Due to zero events in specific cells, 0.5 was added to all cells to calculate an effect estimate.

^2^Percentages in paper recalculated due to assumed rounding error

^3^Unclear which controls were used in the calculation of the effect estimate

10.1371/journal.pone.0206163.t003

###### Risk of bias summary showing judgements about each risk of bias domain.

![](pone.0206163.t003){#pone.0206163.t003g}

  First author, publication yr                                      Confounding   Selection of participants   Misclassification of variables   Bias due to missing data   Reverse Causation
  ----------------------------------------------------------------- ------------- --------------------------- -------------------------------- -------------------------- -------------------
  *VZV reactivation---Herpes zoster*                                                                          ** **                                                        
  Breuer, 2014                                                      •             •                           •                                •                          •
  Calabrese, 2017                                                   ▪             •                           •                                •                          •
  Hosamirudsari, 2018                                               ▪             **◊**                       **◊**                            •                          •
  Kang, 2009                                                        •             •                           •                                •                          •
  Kim, 2017                                                         ◊             •                           •                                •                          •
  Kwon, 2016                                                        **◊**         •                           •                                •                          •
  Langan, 2014                                                      •             •                           •                                •                          •
  Liao, 2017                                                        ▪             •                           •                                •                          •
  Lin, 2010                                                         •             •                           •                                •                          •
  Minassian, 2015                                                   •             •                           •                                •                          •
  Patterson, 2018                                                   **◊**         •                           •                                •                          •
  Schink, 2016                                                      •             •                           •                                •                          •
  Sreenivasan, 2013                                                 ▪             •                           •                                •                          •
  Sundström, 2015                                                   **◊**         **○**                       •                                •                          •
  Tseng, 2011                                                       **○**         •                           •                                •                          •
  Yawn, 2016                                                        •             •                           •                                •                          •
  *CMV infection*                                                                                                                                                         
  Coles, 2003                                                       ▪             •                           •                                •                          •
  Fagerberg, 1999                                                   **◊**         ▪                           •                                •                          •
  González-Quijada, 2015                                            ▪             **◊**                       •                                •                          **◊**
  Huang, 2012                                                       •             ▪                           •                                •                          **◊**
  Kenina, 2010                                                      **◊**         **◊**                       •                                •                          **◊**
  Oliveras, 2003                                                    **◊**         **○**                       •                                •                          •
  Shen, 2011                                                        **◊**         **◊**                       •                                •                          **◊**
  Smieja, 2003                                                      ▪             •                           •                                **○**                      •
  Tarnacka, 2002                                                    **◊**         **◊**                       •                                •                          **◊**
  Yi, 2008                                                          **◊**         **◊**                       •                                •                          **◊**
  Zheng, 2016                                                       •             •                           •                                •                          •
  Ziemann, 2016                                                     **◊**         ▪                           ▪                                •                          •
  *CMV reactivation*                                                                                                                                                      
  Yen, 2016                                                         •             •                           •                                •                          •
  *HHV 6 infection*                                                                                                                                                       
  Fullerton, 2017                                                   **◊**         ▪                           •                                •                          **◊**
  *VZV infection*, *serologically defined*                                                                                                                                
  Asiki, 2015                                                       ▪             **◊**                       ▪                                •                          •
  *VZV infection*, *clinically defined (varicella)*                                                           ** **                                                        
  Askalan, 2001                                                     **◊**         **◊**                       **◊**                            •                          •
  Sébire, 1999                                                      ▪             **◊**                       •                                •                          •
  Thomas, 2014                                                      •             •                           •                                •                          •
  *Vaccination against herpesviruses (e*.*g*. *zostavax vaccine)*                                                                                                         
  Baxter, 2012                                                      •             •                           •                                •                          •
  Kovac, 2018                                                       •             •                           •                                •                          •
  Tseng, 2012                                                       •             •                           •                                •                          •
  Donahue, 2009                                                     •             •                           •                                •                          •
  MacDonaled, 2018                                                  **○**         •                           •                                •                          •
  *Multiple herpesviruses infections*                                                                                                                                     
  Al-Ghamdi, 2012 (HSV-1, CMV, EBV)                                 **◊**         **◊**                       •                                •                          **○**
  Elkind, 2010 (CMV, HSV1 and HSV2)                                 •             •                           ▪                                **○**                      •
  Elkind, 2016 (HSV1/2, CMV, EBV, VZV)                              •             ▪                           •                                •                          **◊**
  Kis, 2007 (HSV-1, CMV, EBV and HHV-6)                             ▪             ▪                           •                                •                          **◊**
  Li, 2005 (CMV, HSV1 and HSV2)                                     **◊**         **◊**                       •                                •                          **◊**
  Ozturk, 2013 (CMV, EBV)                                           ▪             **◊**                       •                                •                          **◊**
  Ridker, 1998 (CMV, HSV1/2)                                        •             **◊**                       •                                **○**                      •
  Sealy-Jefferson, 2013 (CMV, HSV1 and VZV)                         •             •                           **◊**                            •                          •
  Yen, 2017 (HZ and CMV disease)                                    •             •                           •                                •                          •

Key

◊ High risk

▪ Moderate risk

• Low risk

○ Unclear risk

10.1371/journal.pone.0206163.t004

###### Assessment of quality of evidence for outcomes.

![](pone.0206163.t004){#pone.0206163.t004g}

  -------------------------------------------------------------------------- ----------------------- ----------------------------------------------------- ---------------------------------------------------- ------------------ ----------------------------------------------------- -------------------------- ------
  **Quality assessment**                                                     **Quality**                                                                                                                                                                                                                            
  **№ of studies**                                                           **Study design**        **Risk of bias**                                      **Inconsistency**                                    **Indirectness**   **Imprecision**                                       **Other considerations**   
  **VZV: reactivation (herpes zoster)**                                                                                                                                                                                                                                                                             
  17                                                                         observational studies   not serious                                           not serious [^a^](#t004fn002){ref-type="table-fn"}   not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        strong association         ⨁⨁⨁◯
  dose response gradient                                                     MODERATE                                                                                                                                                                                                                               
  **CMV: past infection**                                                                                                                                                                                                                                                                                           
  14                                                                         observational studies   serious [^c^](#t004fn004){ref-type="table-fn"}        not serious [^d^](#t004fn005){ref-type="table-fn"}   not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **CMV: recent infection/reactivation**                                                                                                                                                                                                                                                                            
  11                                                                         observational studies   serious [^c^](#t004fn004){ref-type="table-fn"}        serious [^e^](#t004fn006){ref-type="table-fn"}       not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        strong association         ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HHV6: infection/reactivation**                                                                                                                                                                                                                                                                                  
  1                                                                          observational studies   very serious [^j^](#t004fn011){ref-type="table-fn"}   not serious                                          not serious        very serious [^b^](#t004fn003){ref-type="table-fn"}   none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **EBV: past infection**                                                                                                                                                                                                                                                                                           
  4                                                                          observational studies   serious [^f^](#t004fn007){ref-type="table-fn"}        not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **EBV: recent infection/reactivation**                                                                                                                                                                                                                                                                            
  1                                                                          observational studies   very serious [^h^](#t004fn009){ref-type="table-fn"}   not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        very serious [^b^](#t004fn003){ref-type="table-fn"}   none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-1: past infection**                                                                                                                                                                                                                                                                                         
  4                                                                          observational studies   not serious [^i^](#t004fn010){ref-type="table-fn"}    serious [^e^](#t004fn006){ref-type="table-fn"}       not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-1: recent infection/reactivation**                                                                                                                                                                                                                                                                          
  2                                                                          observational studies   serious [^h^](#t004fn009){ref-type="table-fn"}        serious [^e^](#t004fn006){ref-type="table-fn"}       not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        strong association         ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-2: past infection**                                                                                                                                                                                                                                                                                         
  1                                                                          observational studies   not serious                                           not serious                                          not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-2: recent infection/reactivation**                                                                                                                                                                                                                                                                          
  1                                                                          observational studies   very serious [^j^](#t004fn011){ref-type="table-fn"}   not serious                                          not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-1/2: past infection**                                                                                                                                                                                                                                                                                       
  2                                                                          observational studies   serious [^k^](#t004fn012){ref-type="table-fn"}        not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **HSV-1/2: recent infection/ reactivation**                                                                                                                                                                                                                                                                       
  1                                                                          observational studies   serious [^k^](#t004fn012){ref-type="table-fn"}        not serious                                          not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **VZV infection, serologically defined: past infection**                                                                                                                                                                                                                                                          
  2                                                                          observational studies   serious [^k^](#t004fn012){ref-type="table-fn"}        not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        not serious                                           none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **VZV infection, serologically defined: recent infection/ reactivation**                                                                                                                                                                                                                                          
  1                                                                          observational studies   serious [^k^](#t004fn012){ref-type="table-fn"}        not serious                                          not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        very strong association    ⨁⨁◯◯
  LOW                                                                                                                                                                                                                                                                                                               
  **VZV infection, clinically defined (varicella---adults)**                                                                                                                                                                                                                                                        
  1                                                                          observational studies   not serious                                           not serious                                          not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        strong association         ⨁⨁◯◯
  LOW                                                                                                                                                                                                                                                                                                               
  **VZV infection, clinically defined (varicella---children)**                                                                                                                                                                                                                                                      
  3                                                                          observational studies   serious [^l^](#t004fn013){ref-type="table-fn"}        not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        serious [^b^](#t004fn003){ref-type="table-fn"}        very strong association    ⨁⨁⨁◯
  dose response gradient                                                     MODERATE                                                                                                                                                                                                                               
  **Varicella vaccination**                                                                                                                                                                                                                                                                                         
  2                                                                          observational studies   not serious                                           not serious                                          not serious        very serious [^b^](#t004fn003){ref-type="table-fn"}   none                       ⨁◯◯◯
  VERY LOW                                                                                                                                                                                                                                                                                                          
  **Herpes zoster vaccination**                                                                                                                                                                                                                                                                                     
  3                                                                          observational studies   not serious                                           not serious [^g^](#t004fn008){ref-type="table-fn"}   not serious        not serious                                           none                       ⨁⨁◯◯
  LOW                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------- ----------------------- ----------------------------------------------------- ---------------------------------------------------- ------------------ ----------------------------------------------------- -------------------------- ------

Explanations

a\. None of meta-analyses suffered from considerable heterogeneity and trend of effects were very clear across studies using different study designs.

b\. Wide confidence interval(s)

c\. \<50% studies have two or more domains at high risk of bias and contribute \<50% weight to the meta-analysis

d\. Some point estimates across studies in different directions, some overlap of confidence intervals, where meta-analyses were possible I^2^ statistic indicates substantial heterogeneity (although subgroup analyses demonstrated heterogeneity was driven by a single study).

e\. Some variance of point estimates across studies (yet the majority are in the in same direction), some overlap of confidence intervals, where meta-analyses were possible I^2^ statistic indicates statistical heterogeneity (yet only very few studies included in meta-analyses).

f\. ≥50% studies have two or more domains at high risk of bias, however contribute \<50% weight to the meta-analysis

g\. Some variance of point estimates across studies, confidence intervals overlap, no statistical evidence of heterogeneity

h\. Study/studies suffered from two or more domains at high risk of bias.

i\. 1/4 studies suffered from two domains at high risk of bias; this study only contributed 5% weight to the meta-analyses.

j\. Study may have suffered from three domains at high risk of bias: confounding, reverse causality, and selection bias

k\. Study/studies had one domain at high risk of bias.

l\. 2/3 studies suffered from 2 or more domains at high risk of bias, however one study had a very low risk of bias

17 studies assessed the association between zoster and stroke (1 case-control study,\[[@pone.0206163.ref021]\] 13 cohort studies\[[@pone.0206163.ref022]--[@pone.0206163.ref034]\] and 3 SCCS\[[@pone.0206163.ref035]--[@pone.0206163.ref037]\]) ([Table 1](#pone.0206163.t001){ref-type="table"}). Ten were based in the US or Europe and six in Asia and one in the Middle East; all studies used routinely collected medical records. Two studies involved an immunosuppressed population. 8/17 studies were considered at low-risk of bias in all domains.

Zoster was associated with a 1.5-fold increased stroke risk four weeks following onset (summary estimate: 1.55, 95%CI 1.46--1.65), with the risk decreasing to baseline after around one year ([Fig 2](#pone.0206163.g002){ref-type="fig"}). Removing three studies at high-risk of bias eliminated statistical heterogeneity in cohort studies with "Over 1 year follow-up" (I^2^\<0.01%, see [S1 Table](#pone.0206163.s012){ref-type="supplementary-material"}). There were no SCCS at high-risk of bias. There was moderate quality evidence of an increased risk of stroke following zoster, with evidence upgraded due to some strong associations and a clear dose-response gradient over time.

Two studies reported an increased risk of TIA following zoster. The first showed over 50% increased risk (IRR1.56, 95%CI:1.13--2.15) over a maximum of 10 years follow-up\[[@pone.0206163.ref034]\] and the second around 15% increased risk (HR1.15, 95%CI:1.09--1.21) during a median follow-up of 6.3 years.\[[@pone.0206163.ref022]\] Only a single SCCS study assessed the effect of zoster vaccination on stroke risk, using Medicare claims data; this study found no evidence that zoster vaccination attenuated stroke risk, however only 3% of study participants were vaccinated which limited the study's ability to detect an effect.\[[@pone.0206163.ref035]\]

Results can be found in [S1](#pone.0206163.s006){ref-type="supplementary-material"}, [S2](#pone.0206163.s007){ref-type="supplementary-material"}, [S3](#pone.0206163.s008){ref-type="supplementary-material"}, [S4](#pone.0206163.s009){ref-type="supplementary-material"} and [S5](#pone.0206163.s010){ref-type="supplementary-material"} Figs. Ophthalmic zoster was associated with increased risk of stroke, of a larger magnitude than zoster at any site. The pooled estimate for stroke up to 4 weeks following ophthalmic zoster in SCCSs was 1.77 (95%CI:1.53--2.05), compared to 1.55 (95%CI:1.46--1.65) following any zoster ([S1 Fig](#pone.0206163.s006){ref-type="supplementary-material"}). Another study found the elevated risk of stroke among rheumatoid arthritis patients experiencing zoster was greatest in those patients with a neurological complication.\[[@pone.0206163.ref033]\] Antiviral agents appeared to attenuate stroke risk in two out of three studies, though the confidence intervals for effect estimates for zoster patients given and not given antivirals overlapped ([S2 Fig](#pone.0206163.s007){ref-type="supplementary-material"}). In one SCCS study, in the first four weeks following zoster there appeared to be no evidence of an increased risk of stroke among those given antivirals (IRR1.23, 95%CI:0.89--1.70), whilst for those not given antivirals there was an association (IRR2.14, 95%CI:1.62--2.83). A larger effect of zoster on stroke risk was seen in people aged below 40 years ([S3 Fig](#pone.0206163.s008){ref-type="supplementary-material"}); there was no difference of zoster on stroke risk by gender ([S4 Fig](#pone.0206163.s009){ref-type="supplementary-material"}); and little difference in stroke risk by stroke type (ischaemic versus haemorrhagic), except in one cohort study from Taiwan\[[@pone.0206163.ref024]\] where the magnitude of association was greater for haemorrhagic stroke ([S5 Fig](#pone.0206163.s010){ref-type="supplementary-material"}).

CMV infection, defined largely using laboratory criteria, was investigated in 22 studies\[[@pone.0206163.ref009], [@pone.0206163.ref030], [@pone.0206163.ref038]--[@pone.0206163.ref057]\] using data from a variety of settings including electronic healthcare records, survey data and trial data ([Table 1](#pone.0206163.t001){ref-type="table"}).

Among studies assessing CMV infection (past or recent), 19/22 studies had a least one domain at high-risk of bias, including: confounding (ten studies had no age-adjustment) and reverse causation (10 studies recorded CMV following stroke).

14 studies investigated past CMV infection and stroke risk ([Fig 3](#pone.0206163.g003){ref-type="fig"}); IgG seropositivity and/or high titre IgG antibodies were investigated. IgG seropositivity was not associated with stroke when combining six case-control studies (summary estimate:1.40, 95%CI:0.67--2.96; I^2^ = 78.8%) nor in cohort studies (summary estimate:1.01,95%CI:0.73--1.39, I^2^\<0.001%). While having a high IgG titre compared to a low titre was associated with stroke when combining two case-control studies (summary estimate:2.61,95%CI:1.26--5.43, I^2^ = 33.4%) it was not associated with stroke when pooling three cohort studies (summary estimate:0.80,95%CI:0.62--1.05, I^2^\<0.001%).

Recent CMV infection or reactivation was investigated in 11 case-control studies ([Fig 3](#pone.0206163.g003){ref-type="fig"}), using a variety of exposure definitions. In a meta-analysis of two studies, IgM seropositivity was associated with increased stroke risk (summary estimate:5.53,95%CI:2.83--10.81, I^2^\<0.001%). When pooling three studies, CMV DNA was also associated with increased stroke risk (summary estimate:2.34,95%CI:0.95--5.74, I^2^ = 81.4%). In two of three studies among immunosuppressed patients, clinical CMV reactivation was associated with around 3-fold increased risk of stroke.

There was very low-quality evidence suggesting there is no association between past infection with CMV and stroke and an increased risk of stroke following recent infection/reactivation with CMV.

CMV was the only outcome for which sufficient studies were available to assess publication bias; there was no evidence of publication bias (see [S6 Fig](#pone.0206163.s011){ref-type="supplementary-material"}).

One case-control study assessed the association between HHV-6 and stroke; no association was found.\[[@pone.0206163.ref058]\] Four case-control studies examined the association between EBV and stroke ([Table 1](#pone.0206163.t001){ref-type="table"});\[[@pone.0206163.ref050], [@pone.0206163.ref051], [@pone.0206163.ref053], [@pone.0206163.ref055]\] three were hospital-based among older adults and one a multi-country study among children (under 18 years). All studies were small (N\<500) and at high-risk of bias.

There was no evidence that past infection (IgG seropositivity) was associated with stroke risk, when combining data from three studies (summary estimate: 1.28, 95%CI:0.89--1.84; I^2^\<0.001) ([Fig 4](#pone.0206163.g004){ref-type="fig"}). The study among children found no evidence that recent infection/reactivation of EBV (measured from IgM seropositivity) was associated with stroke risk (OR 1.44, 95% CI 0.12--16.75).

There was very low quality evidence of no association between past infection and an increased risk following recent infection/reactivation with EBV and stroke; the quality of evidence was downgraded due to high-risk of bias and imprecise estimates.

Associations between HSV-1 or HSV-2 and stroke risk were explored in seven studies\[[@pone.0206163.ref050]--[@pone.0206163.ref054], [@pone.0206163.ref056], [@pone.0206163.ref057]\] ([Table 1](#pone.0206163.t001){ref-type="table"}) using population survey data and an RCT, and data from a hospital setting. A high-risk of bias was identified in all seven studies. No clear patterns were observed, although there was some indication that recent HSV1 infection/reactivation (IgM seropositivity or IgA high titre) was associated with increased stroke risk.

Two case-control studies\[[@pone.0206163.ref051], [@pone.0206163.ref059]\] and one US-community based cohort study\[[@pone.0206163.ref057]\] assessed the effect of serologically-defined VZV infection on stroke risk ([Table 1](#pone.0206163.t001){ref-type="table"}). Past infection (IgG seropositivity or high titre) was not associated with stroke risk in two studies ([Fig 4](#pone.0206163.g004){ref-type="fig"}); quality of evidence was graded very low due to a high-risk of bias. However, a multi-country case-control study among children (under 18 years) found recent infection/reactivation (IgM seropositivity) was associated with increased stroke risk; quality of evidence was graded as low, because although there was a high-risk of bias, the association was very strong.

Varicella and the risk of stroke among children was assessed in three studies from Canada and Europe;\[[@pone.0206163.ref060]--[@pone.0206163.ref062]\] a high-risk of bias was identified in 2/3 studies. Different study designs and time periods during which stroke was recorded were used, therefore estimates were not pooled. However, each study found varicella was associated with a greater risk of stroke within a year from diagnosis. Because of the dose-response gradient over time and very strong associations observed, the evidence was classified as moderate quality.

The SCCS study also assessed the association among adults; an increased risk of stroke within 6-months of varicella was found (IR2.13, 95%CI:1.05--4.34). Although this association was strong, the confidence interval was wide, thus the evidence was graded low quality.

Five studies evaluated the short-term effect of VZV vaccination on stroke risk, by comparing vaccinated with unvaccinated people (or person time in the same individuals). One was a multi-country RCT\[[@pone.0206163.ref063]\] and the others used Canadian or US electronic healthcare records ([Table 1](#pone.0206163.t001){ref-type="table"});\[[@pone.0206163.ref064]--[@pone.0206163.ref067]\] these studies were at very low-risk of bias. No decreased risk of stroke in those vaccinated against varicella or zoster was noted ([Fig 4](#pone.0206163.g004){ref-type="fig"}); evidence across studies was graded very low and low quality for varicella and zoster vaccination, respectively.

One small (N = 111) case-control study among older hospitalised patients found no association between HHV-6 IgG seropositivity and stroke ([Table 1](#pone.0206163.t001){ref-type="table"}), in unadjusted analysis (OR 0.90, 95%CI:0.41--1.98).\[[@pone.0206163.ref053]\] No studies assessed herpesvirus-7 or 8.

Discussion {#sec024}
==========

Our review identified 48 studies assessing the association between infection with or reactivation of herpesviruses and risk of stroke. Consistent with previous reviews, there was moderate quality evidence that zoster was associated with a short-term increased risk of stroke, and that increased risk was greatest shortly after zoster (decreasing to baseline by around one year). Some evidence suggested the risk was greater among ophthalmic zoster patients, younger age groups and patients not prescribed antivirals. Moderate quality evidence suggests varicella was associated with increased stroke risk in children. Similar to findings for VZV, there may also be an increased stroke risk with recent CMV and HSV infection/reactivation, however the evidence was very low quality. Finally, there might be an increased stroke risk associated with recent CMV infection or reactivation based on studies carried out in immunosuppressed populations.

Two main pathophysiological mechanisms are proposed by which herpesviruses may increase stroke risk. Systemic infection with, or reactivation of, herpesviruses induces acute inflammation,\[[@pone.0206163.ref002]\] which may lead to endothelial dysfunction accompanied by disruption of atheromatous plaques and hypercoagulability.\[[@pone.0206163.ref068]\] This biological hypothesis is consistent with our finding that latent herpesvirus infection (that is, presence of viral DNA in host cells without producing infectious viral particles)\[[@pone.0206163.ref069]\] does not appear to increase stroke risk, as latent infection does not cause acute inflammation in host cells. Herpesviruses may also directly invade cerebral arteries, producing vasculopathy, leading to increased stroke risk;\[[@pone.0206163.ref070]\] this could explain why younger individuals, normally free from traditional vascular risk factors, were at higher risk of stroke following a recent infection/reactivation of VZV. VZV is the only virus with clear evidence of virus DNA in cerebral arteries; the stronger association between ophthalmic zoster and stroke also supports this hypothesis. CMV is associated with vasculopathy in immunocompromised patients, however the mechanism, and the risk in immunocompetent subjects are unclear.\[[@pone.0206163.ref071]\]

A larger effect of zoster on stroke risk was identified in people aged below 40 years. This has also been reported in a Korean-based cohort study. However, the absolute risk of stroke is low in younger ages, so a large relative effect may be small in absolute terms. This finding, together with the clinical efficacy of the currently available zoster vaccine becoming limited beyond 5--8 years,\[[@pone.0206163.ref072], [@pone.0206163.ref073]\] means vaccinating younger age groups may not be cost-effective.

This is the first study to systematically review the literature on all eight human herpesviruses as stroke risk factors and the results are broadly in-line with previous review assessing individual herpesviruses and cardiovascular disease (including stroke risk).\[[@pone.0206163.ref003]--[@pone.0206163.ref008], [@pone.0206163.ref010]\] Strengths included: following a pre-specified protocol; undertaking a comprehensive search; using articles published in any language; and carrying out a complete risk of bias assessment for each study and an assessment of the accumulated evidence using GRADE. Most studies ascertained stroke from pre-existing health care records (n = 33/41), potentially leading to similar stroke definitions across studies. A further strength of this review is that it not only included studies of clinically apparent herpesviruses reactivation, but subclinical reactivation. A further strength of this review is that it not only included studies of clinically apparent herpesviruses reactivation, but subclinical reactivation. It is possible that those with clinical manifestations of reactivated infection (e.g. zoster), or those who are immunosuppressed (as in some CMV studies), may have higher viral titres which plausibly could affect the risk of short term triggering of stroke.

However, limitations included having little data from low-income countries, which make up around 75% of stroke deaths worldwide;\[[@pone.0206163.ref074]\] whether different populations have different susceptibilities to stroke following herpesvirus infections is unclear. Some meta-analyses combined very few studies, limiting the strength of our pooled results. Overall, the quality of evidence for CMV, EBV and HSV was low or very low.

The studies of VZV, particularly zoster, were well-powered to assess the association between VZV and stroke and rarely suffered from a high-risk of bias; however, subgroup analyses were underpowered, limiting confidence in the findings. Studies of the other herpesviruses (CMV, EBV and HSV) had more limitations; many had small sample sizes, inadequate adjustment for confounders In addition to this, the majority of non-VZV studies relied on laboratory, rather than clinical, identification of possible recent infection or reactivation. The strength of the evidence for zoster and stroke risk lies in the studies all using clear clinical diagnoses of reactivated VZV, which was recorded prior to stroke. In contrast to VZV infection or reactivation which presents with clear clinical symptoms, other herpesviruses may reactivate without any clinical symptoms. Studies that measured markers of infection after stroke may suffer from reverse causality (all but one cases-control study--see [Table 3](#pone.0206163.t003){ref-type="table"}) herpesvirus exposures were defined following stroke and stroke may trigger stress, leading to detection of herpesviruses reactivation after 24 hours (and blood samples were rarely taken immediately after stroke). This may explain why CMV IgG high (versus low) titre was associated with increased stroke risk in most case-control studies,\[[@pone.0206163.ref018]\] but not cohort studies (in which CMV antibodies were recorded prior to stroke). However, most case-control studies used hospital-based controls, so any stress associated with hospitalisation itself may affect cases and controls equally.

In terms of future research, high-powered cohort or SCCS studies assessing the association between recent infection with, and reactivation of, herpesviruses (aside from VZV), ideally collecting serology samples regularly during follow-up are needed. Furthermore, as zoster vaccination uptake increases, better-powered studies could confirm our findings that vaccination is not associated with a short-term increased stroke risk, and establish whether the vaccine reduces the long-term risk of stroke.

In terms of clinical practice, this review indicated that antivirals might attenuate stroke risk among zoster patients. As patients with more severe zoster are more likely to get antivirals, and also potentially more likely to have a stroke, this might have led to underestimation of their effect through confounding by indication. Antiviral drugs shorten zoster healing time and reduce pain severity\[[@pone.0206163.ref075]\] therefore these drugs may plausibly reduce stroke risk, by reducing inflammation. Antivirals for zoster are under-prescribed in UK primary care\[[@pone.0206163.ref076]\] and this review strengthens the argument for better adherence to prescribing guidelines.

Our review highlights that we have a good understanding of a short-term increased stroke risk following VZV infection and reactivation. It also suggests infection and reactivation of other herpesviruses may increase stroke risk, yet better evidence is required. Herpesviruses are common, therefore improved understanding of whether they increase the risk of stroke could provide additional strategies for stroke prevention.

Supporting information {#sec025}
======================

###### Search terms.

(PDF)

###### 

Click here for additional data file.

###### Changes to the original protocol.

(DOCX)

###### 

Click here for additional data file.

###### Extracted data items.

(DOCX)

###### 

Click here for additional data file.

###### Grade assessment of quality: Down/ up-grading reasons.

(DOCX)

###### 

Click here for additional data file.

###### Reference list for selected studies.

(DOCX)

###### 

Click here for additional data file.

###### Effect of clinically diagnosed ophthalmic zoster on stroke risk, by study design and length of follow-up.

(DOCX)

###### 

Click here for additional data file.

###### Effect of zoster on stroke risk by length of follow-up and antiviral use during acute zoster.

(DOCX)

###### 

Click here for additional data file.

###### Effect of zoster on stroke risk by length of follow-up and age group.

(DOCX)

###### 

Click here for additional data file.

###### Effect of zoster on stroke risk by length of follow-up and gender.

(DOCX)

###### 

Click here for additional data file.

###### Effect of zoster on stroke risk by length of follow-up and type of stroke.

(DOCX)

###### 

Click here for additional data file.

###### Assessment of publication bias for CMV IgG seropositivity as a risk factor for stroke.

(DOCX)

###### 

Click here for additional data file.

###### Exploring statistical heterogeneity identified in meta-analyses.

(DOCX)

###### 

Click here for additional data file.

###### Risk of bias.

(PDF)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
